Search
Dexamethasone Treatment Options in United Kingdom
A collection of 187 research studies where Dexamethasone is the interventional treatment. These studies are located in the United Kingdom . Dexamethasone is used for conditions such as Multiple Myeloma, Postoperative Pain and Lymphoma.
37 - 48 of 187
Show Filters
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Male
Female
Both
Type of Study
Interventional
Observational
Clinical Trial Phase
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
Unknown
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
Active Not Recruiting
This is a phase 3, randomized, open-label study of opevesostat compared to alternative abiraterone acetate or enzalutamide in participants with metastatic castration-resistant prostate cancer (mCRPC) with respect to overall survival (OS) and to radiographic progression-free survival (rPFS) per Prostate Cancer Working Group (PCWG) Modified Response Evaluation Criteria In Solid Tumors (RECIST 1.1) as assessed by blinded independent central review (BICR) in participants with mCRPC previously treate... Read More
This is a phase 3, randomized, open-label study of opevesostat compared to alternative abiraterone acetate or enzalutamide in participants with metastatic castration-resistant prostate cancer (mCRPC) with respect to overall survival (OS) and to radiographic progression-free survival (rPFS) per Prostate Cancer Working Group (PCWG) Modified Response Evaluation Criteria In Solid Tumors (RECIST 1.1) as assessed by blinded independent central review (BICR) in participants with mCRPC previously treated with next-generation hormonal agent (NHA) and taxane-based chemotherapy. It is hypothesized that opevesostat is superior with respect to OS and rPFS per PCWG Modified RECIST 1.1 as assessed by BICR in androgen receptor ligand binding domain (AR LBD) mutation-negative and -positive participants. Read Less
Gender:
ALL
Ages:
All
Trial Updated:
07/03/2025
Locations: University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 0040), Orange, California +278 locations
University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 0040), Orange, California
Stanford Cancer Center ( Site 0036), Palo Alto, California
Kaiser Permanente Riverside Medical Center ( Site 0099), Riverside, California
Anschutz Cancer Pavilion ( Site 0046), Aurora, Colorado
University of Colorado Health - Highlands Ranch Hospital ( Site 0111), Highlands Ranch, Colorado
Colorado Clinical Research ( Site 0067), Lakewood, Colorado
University of Colorado Health - Lone Tree Medical Center ( Site 0112), Lone Tree, Colorado
Yale-New Haven Hospital-Yale Cancer Center ( Site 0064), New Haven, Connecticut
Florida Cancer Specialists - South ( Site 7003), Fort Myers, Florida
Bruce W. Carter Veterans Affairs Medical Center ( Site 0082), Miami, Florida
University of Miami Hospital and Clinics, Sylvester Cancer Center ( Site 0051), Miami, Florida
University of Illinois at Chicago ( Site 0105), Chicago, Illinois
University of Chicago Medical Center ( Site 0045), Chicago, Illinois
University of Iowa ( Site 0047), Iowa City, Iowa
University of Kentucky Chandler Medical Center ( Site 0048), Lexington, Kentucky
Ochsner Clinic Foundation ( Site 0108), New Orleans, Louisiana
Baltimore Veterans Affairs Medical Center ( Site 0069), Baltimore, Maryland
Greenebaum Comprehensive Cancer Center ( Site 0049), Baltimore, Maryland
Henry Ford Hospital ( Site 0015), Detroit, Michigan
M Health Fairview Clinics and Surgery Center ( Site 0019), Minneapolis, Minnesota
Metro-Minnesota Community Clinical Oncology ( Site 0014), Saint Louis Park, Minnesota
Washington University School of Medicine-Internal Medicine/Oncology ( Site 0062), Saint Louis, Missouri
University Of Nebraska Medical Center-Oncology/Hematology ( Site 0095), Omaha, Nebraska
Comprehensive Cancer Centers of Nevada ( Site 0010), Las Vegas, Nevada
Atlantic Health System Morristown Medical Center ( Site 0115), Morristown, New Jersey
Rutgers Cancer Institute of New Jersey ( Site 0033), New Brunswick, New Jersey
James J. Peters VA Medical Center ( Site 0088), Bronx, New York
University Hospitals Cleveland Medical Center ( Site 0043), Cleveland, Ohio
Oregon Health and Science University ( Site 0028), Portland, Oregon
VA Portland Health Care System ( Site 0058), Portland, Oregon
AHN Allegheny General Hospital ( Site 0001), Pittsburgh, Pennsylvania
Ralph H. Johnson VA Health Care System (RHJVAHCS)-Urology ( Site 0083), Charleston, South Carolina
Avera Cancer Institute - Pierre ( Site 0118), Pierre, South Dakota
Avera Cancer Institute- Research ( Site 0094), Sioux Falls, South Dakota
Avera Cancer Institute - Yankton ( Site 0117), Yankton, South Dakota
SCRI Oncology Partners ( Site 7000), Nashville, Tennessee
Texas Oncology - Central/South Texas ( Site 8003), Austin, Texas
Texas Oncology - DFW ( Site 8001), Dallas, Texas
Texas Oncology - Gulf Coast ( Site 8002), The Woodlands, Texas
University of Virginia Health System ( Site 0054), Charlottesville, Virginia
VCU Health Adult Outpatient Pavillion ( Site 0061), Richmond, Virginia
Blue Ridge Cancer Care ( Site 0004), Roanoke, Virginia
Fred Hutchinson Cancer Center ( Site 0013), Seattle, Washington
MEDICAL COLLEGE OF WISCONSIN ( Site 0020), Milwaukee, Wisconsin
Hospital Británico de Buenos Aires-Oncology ( Site 0202), Ciudad autónoma de Buenos Aires, Buenos Aires
Instituto de Investigaciones Clínicas Mar del Plata ( Site 0201), Mar del Plata, Buenos Aires
Asociación de Beneficencia Hospital Sirio Libanés ( Site 0205), Buenos Aires, Caba
Instituto Alexander Fleming-Alexander Fleming ( Site 0206), Ciudad Autónoma de Buenos Aires, Caba
Sanatorio Parque ( Site 0208), Rosario, Santa Fe
Hospital Aleman-Oncology ( Site 0207), Buenos Aires, Not set
Fundacion Centro Oncologico de Integración Regional-Medical Oncology ( Site 0204), Mendoza, Not set
Dubbo Hospital ( Site 0235), Dubbo, New South Wales
Macquarie University-MQ Health Clinical Trials Unit ( Site 0234), Macquarie University, New South Wales
Westmead Hospital ( Site 0232), Westmead, New South Wales
Princess Alexandra Hospital-Cancer Care Serices ( Site 0237), Brisbane, Queensland
Peter MacCallum Cancer Centre-Parkville Cancer Clinical Trials Unit (PCCTU) ( Site 0230), Melbourne, Victoria
Ordensklinikum Linz GmbH Elisabethinen-Urologie ( Site 0276), Linz, Oberosterreich
Klinikum Wels-Grieskirchen GmbH ( Site 0279), Wels, Oberosterreich
Medizinische Universität Graz-Innere Medizin Klin. Abt. Onkologie ( Site 0280), Graz, Steiermark
Obras Sociais Irma Dulce ( Site 0302), Salvador, Bahia
Hospital Santa Rita de Cassia-Centro de Pesquisa Clínica ( Site 0320), Vitoria, Espirito Santo
Hospital Felicio Rocho ( Site 0317), Belo Horizonte, Minas Gerais
Hospital Mario Penna ( Site 0309), Belo Horizonte, Minas Gerais
Hospital Universitário Evangélico Mackenzie-Centro de Oncologia Mackenzie ( Site 0314), Curitiba, Parana
Clínica de Neoplasias Litoral ( Site 0305), Itajai, Santa Catarina
Hospital Universitário São Francisco de Assis - Bragança Paulista ( Site 0308), Bragança Paulista, Sao Paulo
A. C. Camargo Cancer Center ( Site 0310), São Paulo, Sao Paulo
Cross Cancer Institute ( Site 0332), Edmonton, Alberta
The Ottawa Hospital - General Campus-The Ottawa Hospital Cancer Centre ( Site 0336), Ottawa, Ontario
Sunnybrook Research Institute ( Site 0331), Toronto, Ontario
Princess Margaret Cancer Centre ( Site 0330), Toronto, Ontario
Centre Intégré de Santé et de Services Sociaux de la Montérégie-Centre ( Site 0328), Greenfield Park, Quebec
Centre Hospitalier de l'Université de Montréal ( Site 0326), Montréal, Quebec
Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus ( Site 0327), Quebec City, Quebec
Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre Hospitalier Univer ( Site 0329), Sherbrooke, Quebec
IC La Serena Research ( Site 0356), La Serena., Coquimbo
Clinical Research Chile SpA ( Site 0358), Valdivia, Los Rios
Clinica Universidad Catolica del Maule-Oncology ( Site 0355), Talca, Maule
FALP ( Site 0353), Santiago, Region M. De Santiago
Pontificia Universidad Catolica de Chile-Hemato-Oncology ( Site 0354), Santiago, Region M. De Santiago
Bradfordhill-Clinical Area ( Site 0351), Santiago, Region M. De Santiago
Bradford Hill Norte ( Site 0357), Antofagasta, Not set
Second Affiliated hospital of Anhui Medical University-Urology ( Site 0408), Hefei, Anhui
Peking University First Hospital-Urology ( Site 0390), Beijing, Beijing
Beijing Friendship Hospital Affiliate of Capital University ( Site 0396), Beijing, Beijing
Beijing Cancer hospital-Urinary Surgery ( Site 0395), Beijing, Beijing
The First Affiliated Hospital of Chongqing Medical University ( Site 0427), Chongqing, Chongqing
Chongqing University Cancer Hospital ( Site 0416), Chongqing, Chongqing
Southwest Hospital of Third Military Medical University ( Site 0420), Chongqing, Chongqing
Chongqing Three Gorges Central Hospital's ( Site 0426), Chongqing, Chongqing
The First Affiliated Hospital Of Fujian Medical University-Urology ( Site 0414), Fuzhou, Fujian
The First Affiliated hospital of Xiamen University-Urology ( Site 0415), Xiamen, Fujian
The First Affiliated Hospital of Guangzhou Medical University ( Site 0412), Guangzhou, Guangdong
Sun Yat-sen University Cancer Center-Internal medicine ( Site 0413), Guangzhou, Guangdong
Tongji Hospital Tongji Medical,Science & Technology ( Site 0407), Wuhan, Hubei
Hubei Cancer Hospital-Urinary surgery ( Site 0406), Wuhan, Hubei
Hunan Cancer Hospital ( Site 0405), Changsha, Hunan
First Huai'an Hospital Affiliated to Nanjing Medical University ( Site 0436), Huaian, Jiangsu
Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School-Urology ( Site 0377), NanJing, Jiangsu
Affiliated hospital of Jiangnan university ( Site 0434), Wuxi, Jiangsu
Jiangxi Cancer Hospital ( Site 0386), Nanchang, Jiangxi
The Second Affiliated Hospital of Xi'an Jiaotong University ( Site 0394), XI An, Shaanxi
The First Affiliated Hospital of Xi'an Jiaotong University-Oncology ( Site 0393), Xi'an, Shaanxi
Yantai Yuhuangding Hospital ( Site 0397), Yantai, Shandong
Fudan University Shanghai Cancer Center-Urology department ( Site 0376), Shanghai, Shanghai
Huadong Hospital Affiliated to Fudan University-Urology ( Site 0388), Shanghai, Shanghai
West China Hospital, Sichuan University-Urology Surgery ( Site 0417), Cheng Du, Sichuan
The Third People's Hospital of Chengdu (CDTPH) ( Site 0428), Chengdu, Sichuan
Nanchong Central Hospital-urology ( Site 0422), Nanchong, Sichuan
Suining Central Hospital ( Site 0437), Suining, Sichuan
Tianjin Medical University Cancer Institute & Hospital ( Site 0392), Tianjin, Tianjin
The Second Hospital of Tianjin Medical University ( Site 0391), Tianjin, Tianjin
Xinjiang Medical University Cancer Hospital - Urumqi-Urology ( Site 0419), Urumqi, Xinjiang
The Second Affiliated Hospital Of Kunming Medical University ( Site 0429), Kunming, Yunnan
Yunnan Province Cancer Hospital ( Site 0418), Kunming, Yunnan
Zhejiang Provincial People's Hospital-Urology ( Site 0378), Hangzhou, Zhejiang
Zhejiang Cancer Hospital ( Site 0435), Hangzhou, Zhejiang
The First Hospital of Jiaxing-urology ( Site 0380), Jiaxing, Zhejiang
The First Affiliated Hospital of Ningbo University ( Site 0383), Ningbo, Zhejiang
The First Affiliated Hospital of Wenzhou Medical University-Urology Surgery ( Site 0379), Wenzhou, Zhejiang
Sociedad De Oncología y Hematología Del Cesar SAS-Oncology ( Site 0502), Valledupar, Cesar
IMAT S.A.S ( Site 0504), Monteria, Cordoba
Clinica Colsanitas S.A, Sede Clínica Universitaria Colombia-Center Investigator ( Site 0501), Bogota, Distrito Capital De Bogota
Fundación Cardiovascular de Colombia ( Site 0503), Piedecuesta, Santander
Fundación Valle del Lili ( Site 0505), Cali, Valle Del Cauca
Clínica Imbanaco S.A.S ( Site 0509), Cali, Valle Del Cauca
Masarykuv onkologicky ustav-Klinika komplexni onkologicke pece ( Site 0553), Brno, Brno-mesto
Fakultni nemocnice Ostrava-Klinika onkologicka ( Site 0554), Ostrava, Moravskoslezsky Kraj
Fakultni nemocnice Olomouc-Onkologicka klinika ( Site 0555), Olomouc, Olomoucky Kraj
Fakultni nemocnice v Motole-Onkologicka klinika 2. LF UK a FN Motol ( Site 0551), Praha, Praha 5
Rigshospitalet ( Site 0576), Copenhagen, Hovedstaden
Odense Universitetshospital-Department of oncology ( Site 0579), Odense, Syddanmark
Vejle Sygehus ( Site 0578), Vejle, Syddanmark
Tampereen yliopistollinen sairaala ( Site 0604), Tampere, Pirkanmaa
Kuopion Yliopistollinen Sairaala ( Site 0603), Kuopio, Pohjois-Savo
Turku University Hospital-Department of Oncology ( Site 0601), Turku, Varsinais-Suomi
Institut de cancérologie Strasbourg Europe (ICANS) ( Site 0627), Strasbourg, Alsace
Centre Hospitalier Universitaire de Nîmes - Institut de Cancérologie du Gard - Hôpital Universitaire ( Site 0630), Nîmes, Gard
Centre Eugène Marquis Rennes - Centre de Lutte Contre le Cancer ( Site 0632), Rennes, Ille-et-Vilaine
Centre Jean Perrin - Centre Régional de Lutte contre le Cancer d'Auvergne ( Site 0629), Clermont-Ferrand, Puy-de-Dome
Centre Hospitalier de la Côte Basque ( Site 0633), Bayonne, Pyrenees-Atlantiques
Gustave Roussy ( Site 0626), Villejuif, Val-de-Marne
Hôpital Européen Georges Pompidou ( Site 0628), Paris, Not set
klinikum rechts der isar der technischen universität münchen-Urologische Klinik und Poliklinik ( Site 0696), Munich, Bayern
HELIOS Kliniken Schwerin ( Site 0694), Schwerin, Mecklenburg-Vorpommern
Universitätsklinikum Bonn-Klinik und Poliklinik für Urologie und Kinderurologie ( Site 0680), Bonn, Nordrhein-Westfalen
Universitätsklinikum Münster - Albert Schweitzer Campus-Klinik für Urologie ( Site 0678), Münster, Nordrhein-Westfalen
Universitätsklinikum Schleswig-Holstein-Klinik für Urologie ( Site 0691), Lubeck, Schleswig-Holstein
Universitätsklinikum Jena-Klinik und Poliklinik für Urologie ( Site 0682), Jena, Thuringen
Charité Universitaetsmedizin Berlin - Campus Mitte ( Site 0679), Berlin, Not set
Universitaetsklinikum Hamburg-Eppendorf-Onkologisches Zentrum ( Site 0705), Hamburg, Not set
Queen Mary Hospital ( Site 0727), Hong Kong, Not set
Prince of Wales Hospital ( Site 0730), Shatin, Not set
Bacs-Kiskun Varmegyei Oktatokorhaz-Onkoradiologiai Kozpont ( Site 0752), Kecskemét, Bacs-Kiskun
Nograd Varmegyei Szent Lazar Korhaz-Onkologia es Sugarterapias Osztaly ( Site 0761), Salgótarján, Nograd
Országos Onkológiai Intézet-Urogenitális Tumorok és Klinikai Farmakológiai Osztály ( Site 0756), Budapest, Pest
Debreceni Egyetem Klinikai Kozpont-Onkológiai Klinika ( Site 0758), Debrecen, Not set
St. Vincent's University Hospital ( Site 0802), Dublin 04, Dublin
Tallaght University Hospital ( Site 0801), Dublin, Not set
Emek Medical Center ( Site 0830), Afula, Not set
Rambam Health Care Campus-Oncology Division ( Site 0826), Haifa, Not set
Hadassah Medical Center ( Site 0833), Jerusalem, Not set
Meir Medical Center. ( Site 0832), Kfar Saba, Not set
Rabin Medical Center ( Site 0828), Petah Tikva, Not set
Sheba Medical Center ( Site 0827), Ramat Gan, Not set
IRCCS - Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori"-Oncologia Medica ( Site 0879), Meldola, Emilia-Romagna
Fondazione IRCCS Istituto Nazionale dei Tumori-Struttura Complessa Oncologia Medica 1 ( Site 0877), Milan, Lombardia
Ospedale San Raffaele-Oncologia Medica ( Site 0876), Milano, Not set
Toho University Sakura Medical Center ( Site 0906), Sakura, Chiba
Ehime University Hospital ( Site 0918), Toon, Ehime
Hospital of the University of Occupational and Environmental Health, Japan ( Site 0921), Kitakyushu, Fukuoka
Kurume University Hospital ( Site 0920), Kurume, Fukuoka
Asahikawa Medical University Hospital ( Site 0901), Asahikawa, Hokkaido
Sapporo Medical University Hospital ( Site 0902), Sapporo, Hokkaido
Hokkaido University Hospital ( Site 0931), Sapporo, Hokkaido
Kobe University Hospital ( Site 0914), Kobe, Hyogo
Kanazawa Medical University Hospital ( Site 0909), Uchinada, Ishikawa
Kagawa University Hospital ( Site 0917), Kita, Kagawa
Yokohama City University Medical Center ( Site 0908), Yokohama, Kanagawa
National Hospital Organization Nagasaki Medical Center ( Site 0923), Ōmura, Nagasaki
Nara Medical University Hospital ( Site 0915), Kashihara, Nara
Nanbu Tokushukai Hospital ( Site 0930), Shimajiri, Okinawa
Kansai Medical University Hospital ( Site 0912), Hirakata, Osaka
Bell Land General Hospital ( Site 0913), Sakai, Osaka
The University of Osaka Hospital ( Site 0911), Suita, Osaka
Saga-Ken Medical Centre Koseikan ( Site 0922), Saga-shi, Saga
The Jikei University Hospital ( Site 0907), Minato, Tokyo
Akita University Hospital ( Site 0904), Akita, Not set
Kyushu University Hospital ( Site 0919), Fukuoka, Not set
Fukushima Medical University Hospital ( Site 0933), Fukushima, Not set
Gifu University Hospital ( Site 0910), Gifu, Not set
Hiroshima University Hospital ( Site 0916), Hiroshima, Not set
Kagoshima University Hospital ( Site 0929), Kagoshima, Not set
National Hospital Organization Kumamoto Medical Center ( Site 0924), Kumamoto, Not set
Miyazaki Prefectural Miyazaki Hospital ( Site 0927), Miyazaki, Not set
University of Miyazaki Hospital ( Site 0926), Miyazaki, Not set
Nagano Municipal Hospital ( Site 0932), Nagano, Not set
National Hospital Organization Oita Medical Center ( Site 0925), Oita, Not set
Asan Medical Center-Oncology ( Site 1402), Songpagu, Seoul
Seoul National University Hospital-Oncology ( Site 1401), Seoul, Not set
Severance Hospital, Yonsei University Health System-Medical oncology ( Site 1404), Seoul, Not set
Samsung Medical Center ( Site 1405), Seoul, Not set
Hospital Sultan Ismail ( Site 1081), Johor Bahru, Johor
University Malaya Medical Centre ( Site 1077), Lembah Pantai, Kuala Lumpur
Sarawak General Hospital-Radiotherapy Unit ( Site 1076), Kuching, Sarawak
National Cancer Institute ( Site 1079), Putrajaya, Wilayah Persekutuan Putrajaya
Hospital Kuala Lumpur-Radiotherapy and Oncology ( Site 1078), Kuala Lumpur, Not set
Quemex Medical and Research ( Site 1112), Mexico City, Distrito Federal
CIO - Centro de Inmuno-Oncología de Occidente ( Site 1103), Guadalajara, Jalisco
Filios Alta Medicina ( Site 1106), Monterrey, Nuevo Leon
Medical Care and Research SA de CV ( Site 1108), Merida, Yucatan
Centro de Investigacion Clinica de Oaxaca ( Site 1109), Oaxaca, Not set
Medische Centrum Leeuwarden ( Site 1172), Leeuwarden, Fryslan
Radboudumc-Medical Oncology ( Site 1152), Nijmegen, Gelderland
Zuyderland Medical Centre-Trialbureau Interne Geneeskunde ( Site 1163), Sittard-Geleen, Limburg
VieCuri Medisch Centrum ( Site 1173), Venlo, Limburg
ETZ Elisabeth-Internal Medicine ( Site 1160), Tilburg, Noord-Brabant
Nederlands Kanker Instituut - Antoni van Leeuwenhoek - NKI-AVL ( Site 1153), Amsterdam, Noord-Holland
Amsterdam UMC, locatie VUmc ( Site 1156), Amsterdam, Noord-Holland
Spaarne Gasthuis - Hoofddorp-Oncology ( Site 1170), Hoofddorp, Noord-Holland
Meander Medisch Centrum ( Site 1157), Amersfoort, Utrecht
Haga Ziekenhuis locatie Leyweg-Oncology ( Site 1164), Den Haag, Zuid-Holland
Franciscus Gasthuis & Vlietland, Locatie Vlietland ( Site 1151), Schiedam, Zuid-Holland
Tauranga Hospital-Bay of Plenty Clinical Trials Unit ( Site 1201), Tauranga, Bay Of Plenty
Dunedin Hospital-Southern Blood and Cancers Service ( Site 1203), Dunedin, Otago
Akershus Universitetssykehus-Onkologisk avdeling ( Site 1227), Lørenskog, Akershus
Sykehuset Østfold Kalnes ( Site 1228), Sarpsborg, Ostfold
St. Olavs Hospital-Kreftklinikken ( Site 1231), Trondheim, Sor-Trondelag
Instituto Regional de Enfermedades Neoplasicas del Centro (IREN CENTRO) ( Site 1258), Concepcion, Junin
Clínica Sánchez Ferrer ( Site 1261), Trujillo, La Libertad
Aliada-Oncologìa ( Site 1257), Lima, Not set
IPOR Instituto Peruano de Oncología & Radioterapia-Centro de Investigación ( Site 1254), Lima, Not set
Oncosalud-Clinical Research ( Site 1260), Lima, Not set
INSTITUTO NACIONAL DE ENFERMEDADES NEOPLASICAS-Medical Oncology ( Site 1256), Lima, Not set
Centrum Onkologii im. Prof. Franciszka Lukaszczyka-Ambulatorium Chemioterapii ( Site 1302), Bydgoszcz, Kujawsko-pomorskie
Regionalny Szpital Specjalistyczny im. dr. Władyslawa Biegańskiego ( Site 1316), Grudziadz, Kujawsko-pomorskie
Wojewodzki Szpital Zespolony im Ludwika Rydygiera w Toruniu ( Site 1304), Torun, Kujawsko-pomorskie
Mazowiecki Szpital Wojewódzki w Siedlcach-Siedleckie Centrum Onkologii ( Site 1310), Siedlce, Mazowieckie
Swietokrzyskie Centrum Onkologii, Samodzielny Publiczny Zakl-Klinika Onkologii Klinicznej, Dzial Ch ( Site 1318), Kielce, Swietokrzyskie
Szpital Wojewódzki im. Mikoaja Kopernika w Koszalinie-Oddzial Dzienny Chemioterapii ( Site 1303), Koszalin, Zachodniopomorskie
Zachodniopomorskie Centrum Onkologii ( Site 1311), Szczecin, Zachodniopomorskie
Puerto Rico Medical Research Center LLC ( Site 1354), Hato Rey, Not set
Ad-Vance Medical Research-Research ( Site 1353), Ponce, Not set
Pan American Center for Oncology Trials - Ciudadela ( Site 1351), San Juan, Not set
National University Hospital ( Site 1376), Singapore, Central Singapore
National Cancer Centre Singapore ( Site 1377), Singapore, Central Singapore
Tan Tock Seng Hospital-Medical Oncology ( Site 1378), Singapore, Central Singapore
Hospital Jerez de la Frontera ( Site 1427), Jerez de la Frontera, Cadiz
Hospital Universitario Ramón y Cajal-Medical Oncology ( Site 1431), Madrid, Madrid, Comunidad De
Hospital Universitario 12 de Octubre-Medical Oncology ( Site 1433), Madrid, Madrid, Comunidad De
Complexo Hospitalario Universitario de Ourense ( Site 1426), Ourense, Orense
Fundación Instituto Valenciano de Oncología-Oncologico ( Site 1430), Valencia, Valenciana, Comunitat
Hospital Lucus Augusti-Oncology ( Site 1432), Lugo, Not set
HOSPITAL UNIVERSITARIO VIRGEN DEL ROCIO-Medical Oncology ( Site 1428), Sevilla, Not set
Karolinska Universitetssjukhuset Solna ( Site 1478), Stockholm, Stockholms Lan
Akademiska sjukhuset-Blod- och tumörsjukdomar ( Site 1477), Uppsala, Uppsala Lan
Sahlgrenska Universitetssjukhuset ( Site 1479), Gothenburg, Vastra Gotalands Lan
China Medical University Hospital-Department of Urology ( Site 1503), Taichung, Not set
National Cheng Kung University Hospital-Urology ( Site 1502), Tainan, Not set
National Taiwan University Hospital-Urology ( Site 1506), Taipei, Not set
Taipei Veterans General Hospital ( Site 1505), Taipei, Not set
Chang Gung Medical Foundation-Linkou Branch-Medical Oncology ( Site 1504), Taoyuan, Not set
Faculty of Medicine - Khon Kaen University ( Site 1526), Muang, Khon Kaen
Chulalongkorn University ( Site 1530), Bangkok, Krung Thep Maha Nakhon
Faculty of Medicine Siriraj Hospital ( Site 1531), Bangkok, Krung Thep Maha Nakhon
Songklanagarind hospital ( Site 1527), Hatyai, Songkhla
Baskent University Dr. Turgut Noyan Research and Training Center-ONCOLOGY ( Site 1554), Adana, Not set
Gulhane Egitim Arastirma Hastanesi ( Site 1558), Ankara, Not set
Hacettepe Universite Hastaneleri-oncology hospital ( Site 1551), Ankara, Not set
Memorial Ankara Hastanesi-Medical Oncology ( Site 1557), Ankara, Not set
Ankara Bilkent Şehir Hastanesi-Medical Oncology ( Site 1552), Ankara, Not set
Istanbul Universitesi Cerrahpasa-Medical Oncology ( Site 1555), Istanbul, Not set
TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi-oncology ( Site 1553), Istanbul, Not set
Addenbrooke's Hospital ( Site 1605), Cambridge, Cambridgeshire
The Royal Cornwall Hospital ( Site 1610), Truro, England
The Beatson West of Scotland Cancer Centre ( Site 1603), Glasgow, Glasgow City
Charing Cross Hospital-Oncology Research ( Site 1606), London, Hammersmith And Fulham
University College London Hospital ( Site 1612), London, London, City Of
The Christie NHS Foundation Trust ( Site 1608), Manchester, Not set
Conditions: Prostate Cancer Metastatic
Perivenous Dexamethasone Therapy: Examining Reduction of Inflammation After Thrombus Removal to Yield Benefit in Acute Femoropopliteal DVT
Recruiting
This is a study of a medical procedure that utilizes a commercially available catheter (the Bullfrog® Micro-Infusion Device) to locally deliver a commercially available anti-inflammatory drug (dexamethasone sodium phosphate injection) around the deep veins after DVT recanalization, where DVT symptoms were present for up to 14 days prior to recanalization. The goal of the study is to see if local anti-inflammation helps prevent re-thrombosis of the blood vessel and improvement in symptoms for up... Read More
This is a study of a medical procedure that utilizes a commercially available catheter (the Bullfrog® Micro-Infusion Device) to locally deliver a commercially available anti-inflammatory drug (dexamethasone sodium phosphate injection) around the deep veins after DVT recanalization, where DVT symptoms were present for up to 14 days prior to recanalization. The goal of the study is to see if local anti-inflammation helps prevent re-thrombosis of the blood vessel and improvement in symptoms for up to 24 months after the initial DVT recanalization procedure. Read Less
Gender:
ALL
Ages:
Between 18 years and 89 years
Trial Updated:
07/01/2025
Locations: Providence St. Joseph Hospital, Orange, California +16 locations
Providence St. Joseph Hospital, Orange, California
Vascular Care Connecticut, Darien, Connecticut
HCA Florida JFK Hospital, Atlantis, Florida
Baptist Health, Jacksonville, Florida
University of South Florida, Tampa, Florida
Piedmont Heart Institute, Atlanta, Georgia
CIS Clinical Research, Houma, Louisiana
Medstar Health Research Institute, Hyattsville, Maryland
Englewood Health, Englewood, New Jersey
Stony Brook University Hospital, Stony Brook, New York
NC Heart and Vascular Research, Raleigh, North Carolina
OhioHealth Research Institute, Columbus, Ohio
St John Health System, Bartlesville, Oklahoma
Allegheny General Hospital, Pittsburgh, Pennsylvania
Sentara Norfolk General Hospital, Norfolk, Virginia
Galway University Hospital, Galway, Not set
Guy's and St. Thomas Hospital, London, Not set
Conditions: Thrombosis, Deep Vein, Iliofemoral; Thrombosis
Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma
Active Not Recruiting
This study will evaluate the safety, pharmacokinetics, pharmacodynamics and clinical activity of belantamab mafodotin in combination with Velcade (bortezomib), Revlimid (lenalidomide), dexamethasone (VRd) and will determine recommended phase 3 dose (RP3D) in adult participants with newly diagnosed multiple myeloma (NDMM). Participants will receive the combination of bortezomib, lenalidomide and dexamethasone (VRd) on a 3-week cycle until cycle 8, followed by the combination of lenalidomide and d... Read More
This study will evaluate the safety, pharmacokinetics, pharmacodynamics and clinical activity of belantamab mafodotin in combination with Velcade (bortezomib), Revlimid (lenalidomide), dexamethasone (VRd) and will determine recommended phase 3 dose (RP3D) in adult participants with newly diagnosed multiple myeloma (NDMM). Participants will receive the combination of bortezomib, lenalidomide and dexamethasone (VRd) on a 3-week cycle until cycle 8, followed by the combination of lenalidomide and dexamethasone (Rd) on a 4-week cycle thereafter as per dosing schedule. Participants will receive belantamab mafodotin on a schedule that is dependent on the cohort to which they are assigned. Belantamab mafodotin will be administered in combination with VRd every 3 weeks (Q3W), every 6 weeks (Q6W), or every 9 weeks (Q9W) to Cycle 8, and then in combination with Rd every 4 weeks (Q4W), every 8 weeks (Q8W), or every 12 weeks (Q12W) thereafter. Participants will complete an End of Treatment (EOT) visit at the point of study treatment discontinuation, followed by a Safety Follow-up visit 70 days after EOT. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/24/2025
Locations: GSK Investigational Site, Westwood, Kansas +29 locations
GSK Investigational Site, Westwood, Kansas
GSK Investigational Site, Charlotte, North Carolina
GSK Investigational Site, Madison, Wisconsin
GSK Investigational Site, Newcastle, New South Wales
GSK Investigational Site, Clayton, Victoria
GSK Investigational Site, Fitzroy, Victoria
GSK Investigational Site, Edmonton, Alberta
GSK Investigational Site, London, Ontario
GSK Investigational Site, Poitiers, Not set
GSK Investigational Site, Dresden, Not set
GSK Investigational Site, Hamburg, Not set
GSK Investigational Site, Schwerin, Not set
GSK Investigational Site, Tuebingen, Not set
GSK Investigational Site, Bologna, Not set
GSK Investigational Site, Meldola FC, Not set
GSK Investigational Site, Seoul, Not set
GSK Investigational Site, Seoul, Not set
GSK Investigational Site, Seoul, Not set
GSK Investigational Site, Lublin, Not set
GSK Investigational Site, Poznan, Not set
GSK Investigational Site, Badalona, Not set
GSK Investigational Site, Barcelona, Not set
GSK Investigational Site, Madrid, Not set
GSK Investigational Site, Malaga, Not set
GSK Investigational Site, PamplonaNavarra, Not set
GSK Investigational Site, Pozuelo De AlarcOn Madr, Not set
GSK Investigational Site, Santander, Not set
GSK Investigational Site, Leicester, Not set
GSK Investigational Site, Oxford, Not set
GSK Investigational Site, Southampton, Not set
Conditions: Multiple Myeloma
A Prospective, Non-interventional, Multinational, Observational Study With Isatuximab in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM)
Active Not Recruiting
Primary Objective:
To assess the effectiveness, in terms of overall response rate (ORR) of isatuximab patients with RRMM in routine clinical practice, within 12 months
To assess other effectiveness parameters such as progression free survival (PFS), PFS rate (PFSR), duration of response (DoR), time to response, time and intent to first subsequent therapy, rate of very good partial response or better, rate of complete response (CR) or better of isatuximab patients with RRMM in routine clinical... Read More
Primary Objective:
To assess the effectiveness, in terms of overall response rate (ORR) of isatuximab patients with RRMM in routine clinical practice, within 12 months
To assess other effectiveness parameters such as progression free survival (PFS), PFS rate (PFSR), duration of response (DoR), time to response, time and intent to first subsequent therapy, rate of very good partial response or better, rate of complete response (CR) or better of isatuximab patients with RRMM in routine clinical practice
To assess the profile of patients (demographic, disease characteristics, comorbidities and prior MM treatment history) who are treated with isatuximab in routine clinical practice
To describe safety of isatuximab in routine clinical practice (based on adverse event \[AE\] reporting)
To assess quality of life (QoL) using the European Organization for Research and Treatment of Cancer (EORTC) 30 item core questionnaire (QLQ C30) and the accompanying 20 item myeloma questionnaire module (QLQ MY20)
Secondary Objective:
Not applicable Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/24/2025
Locations: University of Arkansas Medical Sciences Site Number : 8400021, Little Rock, Arkansas +128 locations
University of Arkansas Medical Sciences Site Number : 8400021, Little Rock, Arkansas
St. Joseph Heritage Healthcare Site Number : 8400008, Fullerton, California
University of California San Francisco (PARENT) Site Number : 8400009, San Francisco, California
Holy Cross Hospital Site Number : 8400030, Fort Lauderdale, Florida
GenesisCare Site Number : 8400007, Jacksonville, Florida
Watson Clinic Cancer and Research Center Site Number : 8400023, Lakeland, Florida
Millennium Oncology Site Number : 8400025, Pembroke Pines, Florida
Comprehensive Hematology Oncology Site Number : 8400026, Saint Petersburg, Florida
Central Care Cancer Center Site Number : 8400019, Garden City, Kansas
Central Maine Medical Center Site Number : 8400031, Lewiston, Maine
Michigan Center of Medical Research Site Number : 8400010, Farmington Hills, Michigan
Central Care Cancer Center Site Number : 8400006, Garden City, Missouri
AMR Kansas City Site Number : 8400016, Kansas City, Missouri
Regional Cancer Care Associates, LLC - Freehold Division Site Number : 8400017, Freehold, New Jersey
Regional Cancer Care Associates Site Number : 8400024, Howell, New Jersey
Regional Cancer Care Associates - Little Silver Division Site Number : 8400018, Little Silver, New Jersey
Novant Health Forsyth Medical Center Site Number : 8400028, Winston-Salem, North Carolina
Hematology & Oncology Associates Site Number : 8400015, Canton, Ohio
Tri County Hematology & Oncology Associates, Inc Site Number : 8400012, Massillon, Ohio
Charleston Hematology Oncology Associates, PA Site Number : 8400020, Charleston, South Carolina
Prisma Health - Eastside Office Site Number : 8400011, Greenville, South Carolina
Prairie Lakes Health Care System, Inc Site Number : 8400002, Watertown, South Dakota
MD Anderson Cancer Center Site Number : 8400013, Houston, Texas
Renovatio Clinical Site Number : 8400004, The Woodlands, Texas
Investigational Site Number : 0320001, Ciudad Autonoma Buenos Aires, Buenos Aires
Investigational Site Number : 0320006, Pilar, Buenos Aires
Investigational Site Number : 0320004, Buenos Aires, Not set
Investigational Site Number : 0320005, Cordoba, Not set
Investigational Site Number : 0320002, Cordoba, Not set
LKH Steyr - Investigational Site Number : 0400002, Steyr, Not set
Institut Jules Bordet - Investigational Site Number : 0560001, Anderlecht, Not set
AZ Nikolaas - Investigational Site Number : 0560002, Sint Niklaas, Not set
Investigational Site Number : 1560002, Guangzhou, Not set
Investigational Site Number : 1560001, Shenzhen, Not set
Centre Hospitalier Victor Dupouy - Investigational Site Number : 2500007, Argenteuil, Not set
Investigational Site Number : 2500017, Cahors, Not set
Centre Hospitalier Metropole Savoie - Investigational Site Number : 2500006, Chambéry, Not set
Clinique Louis Pasteur, Maison Médicale - Investigational Site Number : 2500012, Essey les Nancy, Not set
Centre Hospitalier Le Mans - Investigational Site Number : 2500015, Le Mans Cedex, Not set
Investigational Site Number : 2500013, Lille, Not set
Investigational Site Number : 2500004, Montpellier Cedex 5, Not set
Investigational Site Number : 2500009, Pessac cedex, Not set
CHU Poitiers - Hôpital la Milétrie - Investigational Site Number : 2500008, Poitiers, Not set
CHU Reims - Hôpital Robert Debré - Investigational Site Number : 2500010, Reims, Not set
Investigational Site Number : 2500001, Rouen, Not set
Investigational Site Number : 2500005, Saint Priest En Jarez, Not set
Investigational Site Number : 2500014, Saint Quentin cedex, Not set
Investigational Site Number : 2500016, Tarbes, Not set
Investigational Site Number : 2500011, Vannes Cedex, Not set
Investigational Site Number : 2760016, Aschaffenburg, Not set
Investigational Site Number : 2760020, Bamberg, Not set
Investigational Site Number : 2760018, Bayreuth, Not set
Investigational Site Number : 2760003, Berlin, Not set
Investigational Site Number : 2760041, Berlin, Not set
Praxis am Volkspark - Investigational Site Number : 2760009, Berlin, Not set
Investigational Site Number : 2760022, Berlin, Not set
Investigational Site Number : 2760007, Donauwoerth, Not set
GEFOS Gesellschaft f. onkologische Studien -Investigational Site Number : 2760001, Dortmund, Not set
Investigational Site Number : 2760002, Dresden, Not set
Investigational Site Number : 2760035, Dresden, Not set
Onkologische Gemeinschaftspraxis am Bethanien-Krankenhaus - Investigational Site Number : 2760010, Frankfurt am Main, Not set
Investigational Site Number : 2760037, Frankfurt, Not set
Investigational Site Number : 2760012, Hannover, Not set
Investigational Site Number : 2760013, Herrsching, Not set
MV Zentrum für Onkologie und Hämatologie - Investigational Site Number : 2760034, Koeln, Not set
Klinikum Kulmbach mit Fachklinik Stadtsteinach - Investigational Site Number : 2760026, Kulmbach, Not set
Investigational Site Number : 2760008, Leipzig, Not set
Philipps-Universitat Marburg, Klinic fur Innere Medizin -Investigational Site Number : 2760038, Marburg, Not set
Investigational Site Number : 2760006, Muenchen, Not set
Klinikum Schwaebisch Gmuend - Investigational Site Number : 2760042, Mutlangen, Not set
Dietrich-Bonhoeffer-Klinikum - Investigational Site Number : 2760044, Neubrandenburg, Not set
Investigational Site Number : 2760021, Oldenburg, Not set
Investigational Site Number : 2760036, Oldenburg, Not set
Klinikum Ernst von Bergmann gGmbH -Investigational Site Number : 2760039, Potsdam, Not set
Investigational Site Number : 2760040, Stolberg, Not set
Investigational Site Number : 2760031, Weilheim, Not set
Investigational Site Number : 2760019, Wuerzburg, Not set
Investigational Site Number : 3000005, Piraeus, Not set
Investigational Site Number : 3440001, Hong Kong, Not set
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia - Investigational Site Number : 3800009, Rome, Roma
Azienda Ospedaliera Universitaria Policlinico Umberto I - Investigational Site Number : 3800002, Rome, Roma
Investigational Site Number : 3800006, Bari, Not set
Istituto di Ematologia e Oncologia Medica - Investigational Site Number : 3800005, Bologna, Not set
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia - Investigational Site Number : 3800007, Brescia, Not set
Investigational Site Number : 3800003, Milan, Not set
Azienda Ospedaliera Universitaria "Federico II"-Investigational Site Number : 3800001, Napoli, Not set
Investigational Site Number : 3800008, Novara, Not set
Investigational Site Number : 3800013, Pavia, Not set
Investigational Site Number : 3800004, Trento, Not set
Investigational Site Number : 3800010, Treviso, Not set
Investigational Site Number : 3920012, Sapporo-shi, Hokkaido
Investigational Site Number : 3920009, Osaka-shi, Osaka
Investigational Site Number : 3920003, Sunto-gun, Shizuoka
Investigational Site Number : 3920004, Minato-ku, Tokyo
Investigational Site Number : 3920010, Fukuoka-shi, Not set
Investigational Site Number : 3920013, Minato-ku, Not set
Investigational Site Number : 3920005, Okayama-shi, Not set
Investigational Site Number : 3920014, Osakasayama-shi, Not set
Investigational Site Number : 3920008, Shibukawa-shi, Not set
Investigational Site Number : 3920011, Suwa-shi, Not set
Investigational Site Number : 3920001, Yamagata-shi, Not set
Investigational Site Number : 4140001, Kuwait, Not set
Albert Schweitzer Ziekenhuis - Investigational Site Number : 5820001, Dordrecht, Not set
Puerto Rico Medical Research Center, LLC Site Number : 8400001, Hato Rey, Not set
Auxilio Mutuo Cancer Center Site Number : 8400029, San Juan, Not set
Investigational Site Number : 6430006, Volgograd, Not set
Investigational Site Number : 6820005, Jeddah, Not set
Investigational Site Number : 6820004, Jeddah, Not set
Investigational Site Number : 6820001, Khobar, Not set
Investigational Site Number : 6820002, Riyadh, Not set
Hospital Universitari Son Espases - Investigational Site Number : 7240003, Palma de Mallorca, Baleares
Complejo Asistencial Universitario de Leon Altos de Nava s/n. -Investigational Site Number : 7240005, Leon, León
Hospital Regional Universitario de Malaga Hospital Regional Universitario de Malaga - Investigational Site Number : 7240006, Malaga, Málaga
Hospital Universitario de Navarra - Investigational Site Number : 7240009, Pamplona, Navarra
Hospital Universitario Virgen de la Nieves - Investigational Site Number : 7240010, Granada, Not set
Complejo Hospitalario Universitario de Pontevedra - Investigational Site Number : 7240011, Pontevedra, Not set
omplejo Hospitalario Universitario de Canarias - Investigational Site Number : 7240007, San Cristobal De La Laguna, Not set
Investigational Site Number : 7240004, Toledo, Not set
Kantonsspital Baden AG - Investigational Site Number : 5760003, Baden, Not set
Investigational Site Number : 5760001, Bern, Not set
Stadtspital Triemli - Investigational Site Number : 5760002, Zürich, Not set
Investigational Site Number : 1580002, Kaohsiung, Not set
Investigational Site Number : 1580001, Taipei, Not set
Investigational Site Number : 7840002, Abu Dhabi, Not set
Investigational Site Number : 7840001, Abu dhabi, Not set
Investigational Site Number : 8260002, Nottingham, Nottinghamshire
Investigational Site Number : 8260005, Sutton, Surrey
Huddersfield Royal Infirmary - Investigational Site Number : 8260004, Huddersfield, Not set
Freeman Hospital - Investigational Site Number : 8260003, Newcastle Upon Tyne, Not set
Conditions: Plasma Cell Myeloma
A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.
Active Not Recruiting
A study designed tocompare progression-free survival (PFS) in participants with t(11;14)-positive MM treated with venetoclax in combination with dexamethasone versus pomalidomide in combination with dexamethasone.
A study designed tocompare progression-free survival (PFS) in participants with t(11;14)-positive MM treated with venetoclax in combination with dexamethasone versus pomalidomide in combination with dexamethasone. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/17/2025
Locations: Duplicate_University of Arizona Cancer Center - North Campus /ID# 218407, Tucson, Arizona +179 locations
Duplicate_University of Arizona Cancer Center - North Campus /ID# 218407, Tucson, Arizona
VA Central California Health Care System /ID# 200047, Fresno, California
University of California, Los Angeles /ID# 171524, Los Angeles, California
Rocky Mountain Regional VA Medical Center/Eastern Colorado Health Care System /ID# 222904, Aurora, Colorado
Mayo Clinic /ID# 200075, Jacksonville, Florida
Cleveland Clinic Florida /ID# 208884, Weston, Florida
Duplicate_Norton Cancer Institute /ID# 200834, Louisville, Kentucky
University of Maryland, Baltimore /ID# 217422, Baltimore, Maryland
Boston Medical Center /ID# 223606, Boston, Massachusetts
Barbara Ann Karmanos Cancer In /ID# 201377, Detroit, Michigan
Duplicate_Henry Ford Hospital /ID# 171531, Detroit, Michigan
Mayo Clinic - Rochester /ID# 201091, Rochester, Minnesota
Columbia University Medical Center /ID# 200715, New York, New York
Fairview Hospital - Moll Pavilion /ID# 208919, Cleveland, Ohio
Cleveland Clinic Main Campus /ID# 202247, Cleveland, Ohio
UPMC Hillman Cancer Ctr /ID# 200063, Pittsburgh, Pennsylvania
MD Anderson Cancer Center at Texas Medical Center /ID# 200060, Houston, Texas
Huntsman Cancer Institute /ID# 218406, Salt Lake City, Utah
VA Puget Sound Health Care System /ID# 222708, Seattle, Washington
Liverpool Hospital /ID# 202431, Liverpool, New South Wales
Sydney Adventist Hospital /ID# 222874, Wahroonga, New South Wales
Wollongong Hospital /ID# 205545, Wollongong, New South Wales
ICON Cancer Care - Townsville /ID# 206565, Hyde Park, Queensland
Icon Cancer Centre /ID# 205663, South Brisbane, Queensland
The Queen Elizabeth Hospital /ID# 202432, Woodville South, South Australia
Perth Blood Institute Ltd /ID# 206649, Nedlands, Western Australia
Arthur J. E. Child Comprehensive Cancer Centre /ID# 218846, Calgary, Alberta
BC Cancer - Vancouver /ID# 222804, Vancouver, British Columbia
Queen Elizabeth II Health Sciences Centre - Victoria General /ID# 218883, Halifax, Nova Scotia
CISSS-CA (Centre Integre de sante et de services sociaux de Chaudiere-Appalache) /ID# 218887, Levis, Quebec
Beijing Chaoyang Hospital,Capital Medical University /ID# 216014, Beijing, Beijing
Peking University Third Hospital /ID# 216371, Beijing, Beijing
Peking Union Medical College Hospital (East) - Dongdan Campus /ID# 216040, Beijing, Beijing
Sun Yat-Sen University Cancer Center /ID# 223828, Guangzhou, Guangdong
Guangdong Provincial People's Hospital /ID# 215860, Guangzhou, Guangdong
Henan Cancer Hospital /ID# 215987, Zhengzhou, Henan
Union Hospital Tongji Medical College Huazhong University of Science and Technol /ID# 215850, Wuhan, Hubei
Nanjing Drum Tower Hospital /ID# 223143, Nanjing, Jiangsu
The First Affiliated Hospital of Soochow University /ID# 216094, Suzhou, Jiangsu
The First Affiliated Hospital of Nanchang University /ID# 216954, Nanchang, Jiangxi
The First Hospital of China Medical University /ID# 215996, Shenyang, Liaoning
Shengjing Hospital of China Medical University /ID# 223435, Shenyang, Liaoning
Ruijin Hospital, Shanghai Jiaotong University School of Medicine /ID# 216643, Shanghai, Shanghai
Shanghai Tongji Hospital /ID# 218865, Shanghai, Shanghai
West China Hospital, Sichuan University /ID# 216647, Chengdu, Sichuan
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sc /ID# 216041, Tianjin, Tianjin
Tianjin Medical University Cancer Institute & Hospital /ID# 223550, Tianjin, Tianjin
The First Affiliated Hospital, Zhejiang University School of Medicine /ID# 215989, Hangzhou, Zhejiang
The First Affiliated Hospital, Zhejiang University School of Medicine /ID# 218691, Hangzhou, Zhejiang
The First Affiliated Hospital of Wenzhou Medical University /ID# 218953, Wenzhou, Zhejiang
Beijing Chaoyang Hospital, Capital Medical University(West campus) /ID# 234033, Beijing, Not set
Fakultní Nemocnice Brno - Jihlavská /ID# 204512, Brno, Brno-mesto
Fakultní nemocnice Hradec Králové - Sokolská /ID# 221291, Hradec Králové, Hradec Kralove
Fakultni Nemocnice Ostrava /ID# 204515, Ostrava, Ostrava-mesto
Fakultni nemocnice Olomouc /ID# 221290, Olomouc, Not set
Vseobecna fakultni nemocnice v Praze /ID# 221166, Praha, Not set
Duplicate_Herlev Hospital /ID# 223221, Herlev, Hovedstaden
Aalborg University Hospital /ID# 223220, Aalborg, Nordjylland
Odense University Hospital /ID# 223217, Odense, Syddanmark
Sygehus Lillebalt, Vejle /ID# 223216, Vejle, Syddanmark
Duplicate_Roskilde Hospital /ID# 223366, Roskilde, Not set
Hopital Pitie Salpetriere /ID# 214173, Paris Cedex 13, Ile-de-France
Duplicate_CHU Grenoble - Hopital Michallon /ID# 223182, La Tronche, Isere
CHU Reims - Hôpital Robert Debre /ID# 233907, Reims CEDEX, Marne
CHRU Nancy - Hopitaux de Brabois /ID# 201076, Vandoeuvre-les-Nancy, Meurthe-et-Moselle
CHRU Lille - Hopital Claude Huriez /ID# 202213, Lille, Nord
Hopitaux Universitaires Henri Mondor - Hopital Henri Mondor /ID# 202211, Creteil, Paris
CHU de Nantes, Hotel Dieu -HME /ID# 200099, Nantes, Pays-de-la-Loire
HCL - Hopital Lyon Sud /ID# 200097, Pierre Benite CEDEX, Rhone
Centre Henri Becquerel /ID# 223186, Rouen, Seine-Maritime
CH Henri Duffaut /ID# 234154, Avignon CEDEX 9, Vaucluse
Robert-Bosch-Krankenhaus /ID# 223947, Stuttgart, Baden-Wuerttemberg
Universitaetsklinikum Tuebingen /ID# 238646, Tubingen, Baden-Wuerttemberg
Universitaetsklinikum Wuerzburg /ID# 200055, Wuerzburg, Bayern
Klinikum Chemnitz gGmbH /ID# 233797, Chemnitz, Sachsen
Universitaetsklinikum Schleswig-Holstein Campus Kiel /ID# 201830, Kiel, Schleswig-Holstein
Universitaetsklinikum Jena /ID# 201254, Jena, Thueringen
Charite Universitaetsklinikum Berlin - Campus Benjamin Franklin /ID# 200051, Berlin, Not set
Universitaetsklinikum Hamburg-Eppendorf /ID# 215495, Hamburg, Not set
Asklepios Klinik Altona /ID# 222506, Hamburg, Not set
Alexandra General Hospital /ID# 202386, Athens, Attiki
University General Hospital of Heraklion PA.G.N.I /ID# 222879, Heraklion, Kriti
General Hospital of Athens Evaggelismos and Ophthalmiatrio of Athens Polyclinic /ID# 213982, Athens, Not set
University Gen Hosp of Patra /ID# 201691, Patras, Not set
Theageneio Anticancer Hospital /ID# 213983, Thessaloniki, Not set
General Hospital of Thessaloniki George Papanikolaou /ID# 201692, Thessaloniki, Not set
Rambam Health Care Campus /ID# 169678, Haifa, H_efa
Bnai Zion Medical Center /ID# 169466, Haifa, H_efa
The Lady Davis Carmel Medical Center /ID# 222969, Haifa, H_efa
Duplicate_Assuta Ashdod Medical Center /ID# 222968, Ashdod, HaDarom
Soroka University Medical Center /ID# 218768, Be'er Sheva, HaDarom
The Chaim Sheba Medical Center /ID# 169778, Ramat Gan, Tel-Aviv
Tel Aviv Sourasky Medical Center /ID# 169437, Tel Aviv, Tel-Aviv
Hadassah /ID# 169474, Jerusalem, Yerushalayim
Rabin Medical Center /ID# 244611, Petah Tikva, Not set
Duplicate_IRCCS AOU di Bologna - Policlinico Sant'Orsola-Malpighi /ID# 170952, Bologna, Emilia-Romagna
A.O.U. CITTA' DELLA SALUTE E DELLA SCIENZA DI TORINO - Ospedale Molinette /ID# 170962, Torino, Piemonte
Irccs-Crob /Id# 170955, Rionero In Vulture, Potenza
Azienda Ospedaliero Universitaria delle Marche /ID# 170950, Ancona, Not set
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico /ID# 212498, Milano, Not set
Azienda Ospedaliera Ospedali Riuniti Villa Sofia Cervello /ID# 222988, Palermo, Not set
Azienda Ospedaliera Santa Maria Terni /ID# 170948, Terni, Not set
Nagoya City University Hospital /ID# 170880, Nagoya shi, Aichi
The Jikei University Kashiwa Hospital /ID# 223031, Kashiwa-shi, Chiba
Kyushu University Hospital /ID# 171117, Fukuoka-shi, Fukuoka
Ogaki Municipal Hospital /ID# 171043, Ogaki-shi, Gifu
Gunma University Hospital /ID# 170966, Maebashi-shi, Gunma
Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital /ID# 171255, Hiroshima-shi, Hiroshima
Kobe City Medical Center General Hospital /ID# 170992, Kobe-shi, Hyogo
Duplicate_National Hospital Organization Mito Medical Center /ID# 171187, Higashi Ibaraki-gun, Ibaraki
Hitachi General Hospital /ID# 200843, Hitachi-shi, Ibaraki
Iwate Medical University Hospital /ID# 222849, Shiwa-gun, Iwate
Tohoku University Hospital /ID# 201935, Sendai-shi, Miyagi
Okayama Medical Center /ID# 200119, Okayama-shi, Okayama
Japanese Red Cross Osaka Hospital /ID# 171493, Osaka-shi, Osaka
The University of Osaka Hospital /ID# 201966, Suita-shi, Osaka
Tokushima University Hospital /ID# 202571, Tokushima-shi, Tokushima
The Jikei University Hospital /ID# 239014, Minato-ku, Tokyo
Japanese Red Cross Medical Center /ID# 171256, Shibuya-ku, Tokyo
Yamagata University Hospital /ID# 238329, Yamagata-shi, Yamagata
Duplicate_Gachon University Gil Medical Center /ID# 202827, Incheon, Gyeonggido
Seoul National University Hospital /ID# 202711, Seoul, Seoul Teugbyeolsi
Samsung Medical Center /ID# 202710, Seoul, Seoul Teugbyeolsi
The Catholic University of Korea, Seoul St. Marys Hospital /ID# 234045, Seoul, Seoul Teugbyeolsi
Ulsan University Hospital /ID# 222716, Ulsan, Ulsan Gwang Yeogsi
Yonsei University Health System Severance Hospital /ID# 202709, Seoul, Not set
Moscow State budget healthcare /ID# 169685, Moscow, Moskva
Research Institute of Fundamental and Clinical Immunology /ID# 223594, Novosibirsk, Novosibirskaya Oblast
LLC Novaya Klinika /ID# 169689, Pyatigorsk, Stavropol Skiy Kray
City Clinical Hospital #52 /ID# 206289, Moscow, Not set
Leningrad Regional Clinical Hospital /ID# 202776, Saint Petersburg, Not set
Almazov National Medical Research Centre /ID# 169681, Sankt-Peterburg, Not set
Tula Regional Clinical Hospital /ID# 223226, Tula, Not set
National University Hospital /ID# 203988, Singapore, Not set
Singapore General Hospital /ID# 202131, Singapore, Not set
Tan Tock Seng Hospital /ID# 204374, Singapore, Not set
Hospital Universitari Son Espases /ID# 222889, Palma de Mallorca, Illes Balears
Hospital Costa del Sol /ID# 234083, Marbella, Malaga
Complejo Hospitalario Universitario Ourense /ID# 222876, Orense, Ourense
Hospital Universitario Canarias /ID# 238452, San Cristóbal de La Laguna, Santa Cruz De Tenerife
Hospital Universitario Vall d'Hebron /ID# 218106, Barcelona, Not set
Instituto Catalan de Oncologia (ICO) Girona /ID# 171311, Girona, Not set
Hospital de Leon /ID# 233878, Leon, Not set
Hospital Universitario Fundacion Jimenez Diaz /ID# 171304, Madrid, Not set
Disc_Hospital Universitario 12 de Octubre /ID# 171288, Madrid, Not set
Hospital Universitario La Paz /ID# 218107, Madrid, Not set
Hospital Universitario de Salamanca /ID# 171294, Salamanca, Not set
Hospital Universitario Virgen del Rocio /ID# 171286, Sevilla, Not set
Hospital General Universitario de Toledo /ID# 222887, Toledo, Not set
Hospital Universitario y Politecnico La Fe /ID# 234019, Valencia, Not set
Sunderby sjukhus /ID# 201314, Lulea, Norrbottens Lan
Sodra Alvsborgs sjukhus /ID# 213061, Boras, Vastra Gotalands Lan
Duplicate_Universitetssjukhuset Linköping /ID# 200789, Linkoping, Vastra Gotalands Lan
Uddevalla sjukhus /ID# 201315, Uddevalla, Vastra Gotalands Lan
Cukurova Universitesi Tip Fakultesi /ID# 201955, Saricam Adana, Adana
Izmir Ekonomi Universitesi Ozel Medicalpoint Hastanesi /ID# 201954, Karsiyaka, Izmir
Dr. Abdurrahman Yurtaslan Ankara Onkoloji Egitim ve Arastirma Hastanesi /ID# 201956, Ankara, Not set
Gazi University Medical Faculty /ID# 222698, Ankara, Not set
Ankara Univ Medical Faculty /ID# 201881, Ankara, Not set
Istanbul University Istanbul Medical Faculty /ID# 201953, Istanbul, Not set
Bagcilar Medipol Mega Universite Hastanesi /ID# 222914, Istanbul, Not set
Marmara Universitesi Pendik Egitim ve Arastirma Hastanesi /ID# 201952, Istanbul, Not set
Ege University Medical Faculty /ID# 222697, Izmir, Not set
Communal Nonprofit Enterprise Cherkasy Regional Oncology Dispensary /ID# 223943, Cherkasy, Cherkaska Oblast
Communal non-profit enterprise Regional Center of Oncology /ID# 223945, Kharkiv, Kharkivska Oblast
MNI Khmelnytskyi Regional Hospital of Khmelnytskyi Regional Council /ID# 223942, Khmelnytskyi, Not set
National Cancer Institute /ID# 223944, Kyiv, Not set
SI Institute of Blood Pathology and Transfusion Medicine of NAMS of Ukraine /ID# 223941, Lviv, Not set
Addenbrooke's Hospital /ID# 223097, Cambridge, Cambridgeshire
Hammersmith Hospital /ID# 171446, London, England
University College London Hospital /ID# 171428, London, Greater London
Norfolk and Norwich University Hospitals NHS Foundation Trust /ID# 218213, Norwich, Norfolk
Duplicate_Nottingham University Hospitals NHS Trust /ID# 223292, Nottingham, Nottinghamshire
Duplicate_NHS Greater Glasgow and Clyde /ID# 202199, Glasgow, Scotland
Duplicate_University Hospitals North Midlands - Royal Stoke University Hospital /ID# 218355, Stoke-on-Trent, Staffordshire
Duplicate_Duplicate_Lewisham and Greenwich NHS Trust /ID# 171445, London, Not set
Manchester University NHS Foundation Trust /ID# 171440, Manchester, Not set
Portsmouth Hospitals University NHS Trust /ID# 171444, Portsmouth, Not set
Royal Berkshire NHS Foundation Trust /ID# 217835, Reading, Not set
Duplicate_Sheffield Teaching Hospitals NHS Foundation Trust - Royal Hallamshire /ID# 171447, Sheffield, Not set
Conditions: Multiple Myeloma
Romiplostim Plus Dexamethasone vs Dexamethasone in Patients With Newly Diagnosed Primary Immune Thrombocytopenia
Active Not Recruiting
Phase III, open-labeled, randomized and multicenter clinical trial to evaluate the superiority of romiplostim plus dexamethasone vs dexamethasone alone in patients with newly diagnosed primary immune thrombocytopenia
Phase III, open-labeled, randomized and multicenter clinical trial to evaluate the superiority of romiplostim plus dexamethasone vs dexamethasone alone in patients with newly diagnosed primary immune thrombocytopenia Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/12/2025
Locations: IRCCS AOU di Bologna, Seràgnoli Institute of Hematology, Bologna, Not set +29 locations
IRCCS AOU di Bologna, Seràgnoli Institute of Hematology, Bologna, Not set
ASST Fatebenefratelli Sacco - Ospedale L. Sacco, Milano, Not set
Grande Ospedale Metropolitano Niguarda, Milano, Not set
Azienda Ospedaliero-Universitaria Policlinico Umberto I / SAPIENZA Universitá di Roma, Rome, Not set
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Rome, Not set
Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Not set
Hospital del Mar, Barcelona, Not set
Centre Sociosanitari Sant Jordi de la Vall D'Hebron, Barcelona, Not set
Complejo Asistencial Universitario de Burgos, Burgos, Not set
Complejo Hospitalario Universitario A Coruña, Coruña, Not set
Hospital Universitario Virgen de las Nieves, Granada, Not set
Hospital General Universitario Gregorio Marañón, Madrid, Not set
Compejo Hospitalario La Paz, Madrid, Not set
Hospital Universitario Fundación Alcorcon, Madrid, Not set
Hospital Universitario Morales Meseguer, Murcia, Not set
Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Not set
Hospital Universitario Virgen de la Victoria, Málaga, Not set
Complejo Asistencial Son Espases, Palma De Mallorca, Not set
Complejo Asistencial Universitario de Salamanca, Salamanca, Not set
Hospital Universitario Virgen del Rocío, Sevilla, Not set
Hospital Universitario y Pilitécnico La Fe, Valencia, Not set
University Hospitals Birmingham NHS Foundation Trust, Birmingham, Not set
University Hospitals Bristol and Weston NHS Trust, Bristol, Not set
Haemophilia and Thrombosis Centre, Kent & Canterbury Hospital, Kent & Canterbury Hospital, Ethelbert Road, Canterbury, CT1 3NG, England, UK, Canterbury, Not set
Greater Glasgow and Clyde Health Board, London, Not set
Haematology, Royal Victoria Infirmary, Newcastle, Not set
Norfolk & Norwich University Hospital Trust, Norwich, Not set
Oxford University Hospitals NHS Foundation Trust, Oxford, Not set
"Haematology, Derriford Hospital, University Hospitals Plymouth NHS Trust, Plymouth, Not set
Torbay and South Devon NHS Foundation Trust, Torquay, Not set
Conditions: Primary Immune Thrombocytopenia
Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab
Active Not Recruiting
The purpose of this study is to continue to provide elotuzumab and/or other study drugs to participants who have participated on a prior protocol investigating elotuzumab who are not able to receive commercial drug supply.
The purpose of this study is to continue to provide elotuzumab and/or other study drugs to participants who have participated on a prior protocol investigating elotuzumab who are not able to receive commercial drug supply. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/03/2025
Locations: Local Institution - 0020, Tucson, Arizona +40 locations
Local Institution - 0020, Tucson, Arizona
Local Institution - 0017, Bakersfield, California
Local Institution - 0022, Fountain Valley, California
Local Institution - 0016, West Hollywood, California
Local Institution - 0019, Denver, Colorado
Local Institution - 0021, Jacksonville, Florida
Local Institution - 0042, Saint Petersburg, Florida
Local Institution - 0009, Atlanta, Georgia
Local Institution - 0003, Indianapolis, Indiana
Local Institution - 0002, Boston, Massachusetts
Local Institution - 0008, Saint Louis, Missouri
Local Institution - 0004, New York, New York
Local Institution - 0001, Bethlehem, Pennsylvania
Local Institution - 0018, Dallas, Texas
Local Institution - 0034, Heidelberg, Victoria
Local Institution - 0023, Antwerpen, Not set
Local Institution - 0011, Toronto, Ontario
Local Institution - 0010, Halifax, Not set
Local Institution - 0035, Athens, Not set
Local Institution - 0036, Budapest, Not set
Local Institution - 0015, Ancona, Not set
Local Institution - 0012, Firenze, Not set
Local Institution - 0013, Genova, Not set
Local Institution - 0043, Ravenna, Not set
Local Institution - 0044, Terni, Not set
Local Institution - 0014, Torino, Not set
Local Institution - 0046, Aomori-shi, Aomori
Local Institution - 0047, Shibukawa-shi, Gunma
Local Institution - 0049, Osaka-shi, Osaka
Local Institution - 0048, Koto-ku, Tokyo
Local Institution - 0050, Chiba, Not set
Local Institution - 0045, Kasama-shi, Not set
Local Institution - 0027, Chorzow, Not set
Local Institution - 0026, Warszawa, Not set
Local Institution - 0039, Warszawa, Not set
Local Institution - 0028, Bucuresti, Not set
Local Institution - 0029, Iasi, Not set
Local Institution - 0041, Barcelona, Not set
Local Institution - 0030, Toledo, Not set
Local Institution - 0031, Cebeci Ankara, Not set
Local Institution - 0032, London, Not set
Conditions: Multiple Myeloma
Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
Active Not Recruiting
This open-label, randomized study for evaluating the efficacy and safety of single agent belantamab mafodotin when compared to pom/dex in participants with RRMM. Participants will be randomized in a 2:1 ratio to receive either single agent belantamab mafodotin or pom/dex. Belantamab mafodotin will be administered on Day 1 (D1) at every 3 weeks (Q3W) schedule. Pomalidomide will be administered daily on Days 1 to 21 of each 28-day cycle, with dexamethasone administered once weekly (Days 1, 8, 15,... Read More
This open-label, randomized study for evaluating the efficacy and safety of single agent belantamab mafodotin when compared to pom/dex in participants with RRMM. Participants will be randomized in a 2:1 ratio to receive either single agent belantamab mafodotin or pom/dex. Belantamab mafodotin will be administered on Day 1 (D1) at every 3 weeks (Q3W) schedule. Pomalidomide will be administered daily on Days 1 to 21 of each 28-day cycle, with dexamethasone administered once weekly (Days 1, 8, 15, and 22). Participants in both arms will be treated until disease progression, death, unacceptable toxicity, withdrawal of consent, and lost to follow-up or end of study, whichever comes first. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/28/2025
Locations: GSK Investigational Site, Tucson, Arizona +135 locations
GSK Investigational Site, Tucson, Arizona
GSK Investigational Site, Pueblo, Colorado
GSK Investigational Site, Detroit, Michigan
GSK Investigational Site, Albany, New York
GSK Investigational Site, Clifton Park, New York
GSK Investigational Site, Cincinnati, Ohio
GSK Investigational Site, Corvallis, Oregon
GSK Investigational Site, Eugene, Oregon
GSK Investigational Site, Tyler, Texas
GSK Investigational Site, Milwaukee, Wisconsin
GSK Investigational Site, Gosford NSW, New South Wales
GSK Investigational Site, Liverpool, New South Wales
GSK Investigational Site, St Leonards, New South Wales
GSK Investigational Site, Woodville, South Australia
GSK Investigational Site, Hobart, Tasmania
GSK Investigational Site, Clayton, Victoria
GSK Investigational Site, Fitzroy, Victoria
GSK Investigational Site, Geelong, Victoria
GSK Investigational Site, Nedlands, Western Australia
GSK Investigational Site, St Albans, Not set
GSK Investigational Site, Brugge, Not set
GSK Investigational Site, Brussel, Not set
GSK Investigational Site, Bruxelles, Not set
GSK Investigational Site, Edegem, Not set
GSK Investigational Site, Kortrijk, Not set
GSK Investigational Site, Yvoir, Not set
GSK Investigational Site, Porto Alegre, Rio Grande Do Sul
GSK Investigational Site, Curitiba, Not set
GSK Investigational Site, Fortaleza, Not set
GSK Investigational Site, Porto Alegre, Not set
GSK Investigational Site, Rio de Janeiro, Not set
GSK Investigational Site, SAo Paulo, Not set
GSK Investigational Site, Sao Paulo, Not set
GSK Investigational Site, SAo Paulo, Not set
GSK Investigational Site, SAo Paulo, Not set
GSK Investigational Site, Pleven, Not set
GSK Investigational Site, Plovdiv, Not set
GSK Investigational Site, Sofia, Not set
GSK Investigational Site, Sofia, Not set
GSK Investigational Site, Sofia, Not set
GSK Investigational Site, Sofi, Not set
GSK Investigational Site, Edmonton, Alberta
GSK Investigational Site, Beijing, Not set
GSK Investigational Site, Beijing, Not set
GSK Investigational Site, Beijing, Not set
GSK Investigational Site, Beijing, Not set
GSK Investigational Site, Changsha, Not set
GSK Investigational Site, Chengdu, Not set
GSK Investigational Site, Guangzhou, Not set
GSK Investigational Site, Hangzhou, Not set
GSK Investigational Site, Nanchang, Not set
GSK Investigational Site, Shenzhen, Not set
GSK Investigational Site, Tianjin, Not set
GSK Investigational Site, Tianjin, Not set
GSK Investigational Site, Xuzhou, Not set
GSK Investigational Site, Zhengzhou, Not set
GSK Investigational Site, Le Mans, Not set
GSK Investigational Site, Montpellier, Not set
GSK Investigational Site, Poitiers, Not set
GSK Investigational Site, Berlin, Not set
GSK Investigational Site, Tuebingen, Not set
GSK Investigational Site, Athens, Not set
GSK Investigational Site, Athens, Not set
GSK Investigational Site, Haidari - Athens, Not set
GSK Investigational Site, Larissa, Not set
GSK Investigational Site, Patra, Not set
GSK Investigational Site, Thessaloniki, Not set
GSK Investigational Site, Thessaloniki, Not set
GSK Investigational Site, Budapest, Not set
GSK Investigational Site, Budapest, Not set
GSK Investigational Site, Budapest, Not set
GSK Investigational Site, Debrecen, Not set
GSK Investigational Site, KaposvAr, Not set
GSK Investigational Site, Nyiregyhaza, Not set
GSK Investigational Site, Bologna, Not set
GSK Investigational Site, Brescia, Not set
GSK Investigational Site, Catanzaro, Not set
GSK Investigational Site, Milano, Not set
GSK Investigational Site, Milano, Not set
GSK Investigational Site, Pavia, Not set
GSK Investigational Site, Perugia, Not set
GSK Investigational Site, Ravenna, Not set
GSK Investigational Site, Roma, Not set
GSK Investigational Site, San Giovanni Rotondo FG, Not set
GSK Investigational Site, Siena, Not set
GSK Investigational Site, Aichi, Not set
GSK Investigational Site, Chiba, Not set
GSK Investigational Site, Ehime, Not set
GSK Investigational Site, Fukushima, Not set
GSK Investigational Site, Gifu, Not set
GSK Investigational Site, Gunma, Not set
GSK Investigational Site, Hokkaido, Not set
GSK Investigational Site, Kyoto, Not set
GSK Investigational Site, Kyoto, Not set
GSK Investigational Site, Osaka, Not set
GSK Investigational Site, Tokyo, Not set
GSK Investigational Site, Tokyo, Not set
GSK Investigational Site, Gyeonggi-do, Not set
GSK Investigational Site, Hwasun, Not set
GSK Investigational Site, Incheon, Not set
GSK Investigational Site, Seongnam-si Gyeonggi-do, Not set
GSK Investigational Site, Seoul, Not set
GSK Investigational Site, Seoul, Not set
GSK Investigational Site, Seoul, Not set
GSK Investigational Site, Amersfoort, Not set
GSK Investigational Site, Gdansk, Not set
GSK Investigational Site, Krakow, Not set
GSK Investigational Site, Torun, Not set
GSK Investigational Site, Ekaterinburg, Not set
GSK Investigational Site, Kaluga, Not set
GSK Investigational Site, Kirov, Not set
GSK Investigational Site, Krasnoyarsk, Not set
GSK Investigational Site, Nizhny Novgorod, Not set
GSK Investigational Site, Novosibirsk, Not set
GSK Investigational Site, Saint Petersburg, Not set
GSK Investigational Site, Samara, Not set
GSK Investigational Site, Sochi, Not set
GSK Investigational Site, St Petersburg, Not set
GSK Investigational Site, Syktyvkar, Not set
GSK Investigational Site, Tula, Not set
GSK Investigational Site, Barcelona, Not set
GSK Investigational Site, Barcelona, Not set
GSK Investigational Site, L'Hospitalet De Llobrega, Not set
GSK Investigational Site, Malaga, Not set
GSK Investigational Site, PamplonaNavarra, Not set
GSK Investigational Site, Pozuelo De AlarcOn Madr, Not set
GSK Investigational Site, Santiago de Compostela, Not set
GSK Investigational Site, Airdrie, Not set
GSK Investigational Site, Dundee, Not set
GSK Investigational Site, Edinburgh, Not set
GSK Investigational Site, London, Not set
GSK Investigational Site, London, Not set
GSK Investigational Site, Nottingham, Not set
GSK Investigational Site, Oxford, Not set
GSK Investigational Site, Plymouth, Not set
GSK Investigational Site, Stoke-on-Trent, Not set
Conditions: Multiple Myeloma
A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma
Recruiting
The purpose of this study is to compare the efficacy of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Ciltacabtagene Autoleucel versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Autologous Stem Cell Transplant (ASCT) in newly diagnosed multiple myeloma patients.
The purpose of this study is to compare the efficacy of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Ciltacabtagene Autoleucel versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Autologous Stem Cell Transplant (ASCT) in newly diagnosed multiple myeloma patients. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/26/2025
Locations: University of Arkansas, Little Rock, Arkansas +108 locations
University of Arkansas, Little Rock, Arkansas
City of Hope, Duarte, California
UC San Diego Health Moores Cancer Center, San Diego, California
University of California San Francisco (UCSF), San Francisco, California
Stanford University, Stanford, California
Moffitt Cancer Center, Tampa, Florida
Emory University Hospital, Atlanta, Georgia
University of Chicago, Chicago, Illinois
University of Iowa, Iowa City, Iowa
University Of Maryland Medical Center, Baltimore, Maryland
Massachusetts General Hospital, Boston, Massachusetts
Boston Medical Center, Boston, Massachusetts
Beth Israel Deaconess Medical Center, Boston, Massachusetts
Dana-Farber Cancer Institute, Boston, Massachusetts
Karmanos Cancer Center, Detroit, Michigan
Mayo Clinic Hospital - Rochester, Rochester, Minnesota
Montefiore M-E Center, Bronx, New York
Mount Sinai Medical Venter, New York, New York
Memorial Sloan-Kettering Cancer Center, New York, New York
University of Rochester, Rochester, New York
Levine Cancer Institute, Charlotte, North Carolina
Duke University Medical Center, Durham, North Carolina
Cleveland Clinic, Cleveland, Ohio
The Ohio State University, Columbus, Ohio
Thomas Jefferson University Hospital, Philadelphia, Pennsylvania
University of Texas Southwestern Medical Center, Dallas, Texas
University of Virginia, Charlottesville, Virginia
Fred Hutchinson Cancer Center, Seattle, Washington
Medical College Wisconsin, Milwaukee, Wisconsin
Princess Alexandra Hospital, Brisbane, Not set
Royal Prince Alfred Hospital, Camperdown, Not set
Royal Brisbane and Womens Hospital, Herston, Not set
Alfred Health, Melbourne, Not set
Austin Hospital, Melbourne, Not set
Peter MacCallum Cancer Centre, Melbourne, Not set
Fiona Stanley Hospital, Murdoch, Not set
Calvary Mater Newcastle Hospital, Waratah, Not set
Westmead Hospital, Westmead, Not set
Jules Bordet Instituut, Anderlecht, Not set
UZA, Antwerpen, Not set
UZ Gent, Gent, Not set
UZ Leuven, Leuven, Not set
Cross Cancer Institute, Edmonton, Not set
McMaster University, Hamilton, Not set
Hopital Maisonneuve-Rosemont, Montréal, Not set
Mcgill University Health Centre, Montréal, Not set
Ottawa Hospital Research Institute, Ottawa, Not set
(CHU) Centre Hospitalier Universitaire de Quebec Laval, Québec, Not set
Princess Margaret Cancer Centre, Toronto, Not set
Vancouver General Hospital, Vancouver, Not set
Fakultni nemocnice Brno, Brno, Not set
Fakultni nemocnice Hradec Kralove, Králová, Not set
Fakutni nemocnice Ostrava, Ostrava, Not set
Fakultni nemocnice Plzen, Plzen, Not set
Vseobecna fakultni nemocnice v Prague, Prague, Not set
CHRU de Lille - Hopital Claude Huriez, Lille, Not set
Hospices Civils De Lyon, Lyon, Not set
CHU De Nantes - Hématologie Clinique, Nantes, Not set
CHU Poitiers - Pôle régional de Cancérologie, Poitiers, Not set
Hopital Saint Louis - Aphp Hôpitaux Universitaires Saint-Louis, Saint-Louis, Not set
CHU de Toulouse, Toulouse, Not set
University Hospital of Cologne, Cologne, Not set
Universitätsklinikum Hamburg - Eppendorf, Hamburg, Not set
University Hospital of Leipzig, Leipzig, Not set
Tübingen, Tübingen, Not set
University Hospital of Würzburg, Würzburg, Not set
Attikon University General Hospital of Attica, Athens, Not set
'G. Papanikolaou' Hospital of Thessaloniki, Thessaloníki, Not set
Hadassah Medical Center, Jerusalem, Not set
Sheba medical center, Ramat Gan, Not set
Tel Aviv Sourasky Medical Center, Tel Aviv, Not set
Juntendo University Hospital, Bunkyō-Ku, Not set
Kyushu University Hospital - Hematology/Oncology, Fukuoka, Not set
Hokkaido University Hospital-Department of Hematology, Hokkaido, Not set
Hyogo College of Medicine, Hyōgo, Not set
Kanazawa University Hospital, Kanazawa, Not set
Nagoya City University Hospital - Department of Hematology & Oncology, Nagoya, Not set
Okayama University Hospital - Hematology/Oncology, Okayama, Not set
Osaka metropolitan university hospital, Osaka, Not set
Japanese Red Cross Medical Center - Hematology, Shibuya, Not set
Keio University Hospital - Hematology, Shinjuku-Ku, Not set
Tohoku University Hospital - Hematology, Tōhoku, Not set
VU Medisch Centrum, Amsterdam, Not set
University Medical Center Groningen, Groningen, Not set
Radboud UMC, Nijmegen, Not set
Erasmus MC, Rotterdam, Not set
UMC Utrecht, Utrecht, Not set
Oslo University Hospital Ullevål - Oncology, Oslo, Not set
Hospital Universitario Germans Trias i Pujol, Badalona, Not set
Hospital Clinic de Barcelona, Barcelona, Not set
Instituto Catalán de Oncología, Barcelona, Not set
Hospital Universitario Ramón y Cajal, Madrid, Not set
Hospital General Universitario Gregorio Marañón, Madrid, Not set
Hospital Universitario 12 de Octubre, Madrid, Not set
CLINICA UNIV. DE NAVARRA, Pamplona, Pamplona, Not set
Hospital Universitario de Salamanca, Salamanca, Not set
Hospital de Santiago de Compostela, Santiago De Compostela, Not set
Hospital Universitario Virgen del Rocío, Sevilla, Not set
Hospital Universitario la Fe, Valencia, Valencia, Not set
Sahlgrenska Universitetssjukhuset, Göteborg, Not set
Landstinget i Ostergotland-Universitetssjukhuset i Linkoping, Linköping, Not set
Skånes University Hospital Lund, Lund, Not set
Akademiska Sjukhuset, Uppsala, Not set
Universitaetsspital Basel - Zentrum fur Hamato-Onkologie, Basel, Not set
Universitaetsspital Bern, Inselspital, Bern, Not set
Centre Hospitalier Universitaire Vaudois (CHUV)Département d'oncologie, Lausanne, Not set
Universitaetsspital Zuerich -Universitaeren Herzzentrum Zuerich, Zürich, Not set
Queen Elizabeth Medical Centre, Birmingham, Not set
University Hospital of Wales, Cardiff, Not set
Conditions: Multiple Myeloma
Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma
Completed
The purpose of this study is to compare the efficacy of daratumumab in combination with lenalidomide and dexamethasone to that of lenalidomide and dexamethasone in terms of progression-free survival (PFS) in participants with newly diagnosed multiple myeloma (a blood cancer of plasma cells) who are not candidates for high dose chemotherapy (treatment of disease, usually cancer, by chemical agents) and autologous stem cell transplant (ASCT).
The purpose of this study is to compare the efficacy of daratumumab in combination with lenalidomide and dexamethasone to that of lenalidomide and dexamethasone in terms of progression-free survival (PFS) in participants with newly diagnosed multiple myeloma (a blood cancer of plasma cells) who are not candidates for high dose chemotherapy (treatment of disease, usually cancer, by chemical agents) and autologous stem cell transplant (ASCT). Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/23/2025
Locations: Not set, Birmingham, Alabama +209 locations
Not set, Birmingham, Alabama
Not set, Mobile, Alabama
Not set, Glendale, Arizona
Not set, Berkeley, California
Not set, Beverly Hills, California
Not set, El Cajon, California
Not set, Greenbrae, California
Not set, Los Angeles, California
Not set, Oceanside, California
Not set, San Diego, California
Not set, West Hills, California
Not set, Whittier, California
Not set, Denver, Colorado
Not set, Fort Collins, Colorado
Not set, Glenwood Springs, Colorado
Not set, New Haven, Connecticut
Not set, Norwalk, Connecticut
Not set, Washington, District of Columbia
Not set, Boca Raton, Florida
Not set, Boynton Beach, Florida
Not set, Fort Lauderdale, Florida
Not set, Fort Myers, Florida
Not set, Hollywood, Florida
Not set, Jacksonville, Florida
Not set, Lake City, Florida
Not set, Saint Petersburg, Florida
Not set, Weston, Florida
Not set, Atlanta, Georgia
Not set, Augusta, Georgia
Not set, Macon, Georgia
Not set, Marietta, Georgia
Not set, Chicago, Illinois
Not set, Niles, Illinois
Not set, Fort Wayne, Indiana
Not set, Iowa City, Iowa
Not set, Louisville, Kentucky
Not set, Lafayette, Louisiana
Not set, Marrero, Louisiana
Not set, Shreveport, Louisiana
Not set, Annapolis, Maryland
Not set, Baltimore, Maryland
Not set, Frederick, Maryland
Not set, Boston, Massachusetts
Not set, Detroit, Michigan
Not set, Duluth, Minnesota
Not set, Rochester, Minnesota
Not set, Kansas City, Missouri
Not set, Saint Louis, Missouri
Not set, Omaha, Nebraska
Not set, Hooksett, New Hampshire
Not set, Brick, New Jersey
Not set, Hackensack, New Jersey
Not set, Livingston, New Jersey
Not set, Plainfield, New Jersey
Not set, Summit, New Jersey
Not set, Mineola, New York
Not set, New York, New York
Not set, Rochester, New York
Not set, Asheboro, North Carolina
Not set, Charlotte, North Carolina
Not set, Pinehurst, North Carolina
Not set, Winston-Salem, North Carolina
Not set, Canton, Ohio
Not set, Cleveland, Ohio
Not set, Columbus, Ohio
Not set, Bend, Oregon
Not set, Bethlehem, Pennsylvania
Not set, Pittsburgh, Pennsylvania
Not set, Spartanburg, South Carolina
Not set, Sioux Falls, South Dakota
Not set, Chattanooga, Tennessee
Not set, Nashville, Tennessee
Not set, Arlington, Texas
Not set, Edinburg, Texas
Not set, Fort Sam Houston, Texas
Not set, Fort Worth, Texas
Not set, Houston, Texas
Not set, Plano, Texas
Not set, San Antonio, Texas
Not set, Ogden, Utah
Not set, Seattle, Washington
Not set, Spokane, Washington
Not set, Tacoma, Washington
Not set, Box Hill, Not set
Not set, Fitzroy, Not set
Not set, Footscray, Not set
Not set, Kogarah, Not set
Not set, Kurralta Park, Not set
Not set, Nedlands, Not set
Not set, New South Wales, Not set
Not set, Woodville, Not set
Not set, Woolloongabba N/a, Not set
Not set, Innsbruck, Not set
Not set, Linz, Not set
Not set, Salzburg, Not set
Not set, Wien N/a, Not set
Not set, Wien Wien, Not set
Not set, Brugge, Not set
Not set, Brussels, Not set
Not set, Brussel, Not set
Not set, Haine Saint Paul La Louviere, Not set
Not set, Leuven, Not set
Not set, Liege, Not set
Not set, Calgary, Alberta
Not set, Toronto, Ontario
Not set, Greenfield Park, Quebec
Not set, Montreal, Quebec
Not set, Montréal, Quebec
Not set, N/a N/a, Not set
Not set, Nova Scotia, Not set
Not set, Quebec, Not set
Not set, Aarhus C, Not set
Not set, Odense, Not set
Not set, Vejle, Not set
Not set, Amiens N/a Picardie, Not set
Not set, Angers, Not set
Not set, Bayonne Cedex, Not set
Not set, Bretagne, Not set
Not set, Caen, Not set
Not set, Cergy Pontoise, Not set
Not set, Chalons Sur Saone, Not set
Not set, Clermont-Ferrand, Not set
Not set, Creteil, Not set
Not set, Dijon, Not set
Not set, Dunkerque Cedex 1, Not set
Not set, Grenoble Cedex 9, Not set
Not set, La Roche sur Yon Cedex 9, Not set
Not set, Le Chesnay Cedex, Not set
Not set, Le Mans, Not set
Not set, Lille Cedex, Not set
Not set, Lille, Not set
Not set, Limoges, Not set
Not set, Lyon, Not set
Not set, Marseille Cedex 9, Not set
Not set, Metz-Tessy, Not set
Not set, Montivilliers, Not set
Not set, Montpellier, Not set
Not set, Mulhouse, Not set
Not set, Nantes, Not set
Not set, Nice N/a, Not set
Not set, Paris Cedex 12, Not set
Not set, Paris, Not set
Not set, PERIGUEUX cedex, Not set
Not set, Perpignan, Not set
Not set, Pessac, Not set
Not set, Poitiers, Not set
Not set, Reims, Not set
Not set, Rennes, Not set
Not set, Rouen Cedex, Not set
Not set, Saint Brieuc Cedex 1, Not set
Not set, Saint Priest en Jarez, Not set
Not set, St Malo Cedex, Not set
Not set, St Quentin Cedex, Not set
Not set, Strasbourg, Not set
Not set, Toulouse Cedex 9, Not set
Not set, TOURS Cedex 9, Not set
Not set, Vandoeuvre Les Nancy, Not set
Not set, Aschaffenburg, Not set
Not set, Bad Berka, Not set
Not set, Bonn, Not set
Not set, Braunschweig, Not set
Not set, Dresden, Not set
Not set, Essen, Not set
Not set, Frankfurt, Not set
Not set, Hannover, Not set
Not set, Heidelberg, Not set
Not set, Hessen, Not set
Not set, Kiel, Not set
Not set, Koblenz, Not set
Not set, Mainz, Not set
Not set, Mannheim, Not set
Not set, Rostock, Not set
Not set, Schwerin, Not set
Not set, Stuttgart, Not set
Not set, Tuebingen, Not set
Not set, Ulm, Not set
Not set, Villingen-Schwenningen, Not set
Not set, Dublin, Not set
Not set, Galway, Not set
Not set, Hadera, Not set
Not set, Haifa, Not set
Not set, Jerusalem, Not set
Not set, Nahariya, Not set
Not set, Petah Tikva, Not set
Not set, Tel-Aviv, Not set
Not set, Hilversum, Not set
Not set, Hoofddorp, Not set
Not set, Rotterdam, Not set
Not set, Tilburg, Not set
Not set, Falun, Not set
Not set, Göteborg, Not set
Not set, Halmstad, Not set
Not set, Helsingborg, Not set
Not set, Huddinge, Not set
Not set, Lulea, Not set
Not set, Lund, Not set
Not set, Stockholm, Not set
Not set, Örebro, Not set
Not set, Aberdeen, Not set
Not set, Canterbury, Not set
Not set, Dundee, Not set
Not set, Leeds, Not set
Not set, London, Not set
Not set, Manchester, Not set
Not set, Nottingham, Not set
Not set, Oxford, Not set
Not set, Plymouth, Not set
Not set, Southampton, Not set
Not set, Truro, Not set
Not set, Wolverhampton, Not set
Conditions: Multiple Myeloma
A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)
Active Not Recruiting
AL (or light chain) amyloidosis begins in the bone marrow where abnormal proteins misfold and create free light chains that cannot be broken down. These free light chains bind together to form amyloid fibrils that build up in the extracellular space of organs, affecting the kidneys, heart, liver, spleen, nervous system and digestive tract.
The primary purpose of this study is to determine whether CAEL-101, a monoclonal antibody that removes AL amyloid deposits from tissues and organs, improves... Read More
AL (or light chain) amyloidosis begins in the bone marrow where abnormal proteins misfold and create free light chains that cannot be broken down. These free light chains bind together to form amyloid fibrils that build up in the extracellular space of organs, affecting the kidneys, heart, liver, spleen, nervous system and digestive tract.
The primary purpose of this study is to determine whether CAEL-101, a monoclonal antibody that removes AL amyloid deposits from tissues and organs, improves overall survival, reduces cardiovascular related hospitalizations and it is safe and well tolerated in patients with stage IIIa AL amyloidosis. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/22/2025
Locations: Research Site, Scottsdale, Arizona +109 locations
Research Site, Scottsdale, Arizona
Research Site, Duarte, California
Research Site, Palo Alto, California
Research Site, San Francisco, California
Research Site, Jacksonville, Florida
Research Site, Weston, Florida
Research Site, Indianapolis, Indiana
Research Site, New Orleans, Louisiana
Research Site, Baltimore, Maryland
Research Site, Boston, Massachusetts
Research Site, Boston, Massachusetts
Research Site, Boston, Massachusetts
Research Site, Detroit, Michigan
Research Site, Rochester, Minnesota
Research Site, Saint Louis, Missouri
Research Site, New York, New York
Research Site, New York, New York
Research Site, Rochester, New York
Research Site, Chapel Hill, North Carolina
Research Site, Durham, North Carolina
Research Site, Winston-Salem, North Carolina
Research Site, Cleveland, Ohio
Research Site, Columbus, Ohio
Research Site, Portland, Oregon
Research Site, Philadelphia, Pennsylvania
Research Site, Nashville, Tennessee
Research Site, Dallas, Texas
Research Site, Houston, Texas
Research Site, Salt Lake City, Utah
Research Site, Seattle, Washington
Research Site, Madison, Wisconsin
Research Site, Milwaukee, Wisconsin
Research Site, Box Hill, Not set
Research Site, Murdoch, Not set
Research Site, Westmead, Not set
Research Site, Woolloongabba, Not set
Research Site, Linz, Not set
Research Site, Vienna, Not set
Research Site, Anderlecht, Not set
Research Site, Leuven, Not set
Research Site, Porto Alegre, Not set
Research Site, Ribeirão Preto, Not set
Research Site, Salvador, Not set
Research Site, Calgary, Alberta
Research Site, Toronto, Ontario
Research Site, Beijing, Not set
Research Site, Beijing, Not set
Research Site, Guangzhou, Not set
Research Site, Hangzhou, Not set
Research Site, Shanghai, Not set
Research Site, Suzhou, Not set
Research Site, Wenzhou, Not set
Research Site, Wuhan, Not set
Research Site, Ostrava Poruba, Not set
Research Site, Prague, Not set
Research Site, Caen, Not set
Research Site, Creteil, Not set
Research Site, Dijon, Not set
Research Site, Lille, Not set
Research Site, Limoges, Not set
Research Site, Marseille, Not set
Research Site, Paris, Not set
Research Site, Pessac, Not set
Research Site, Pierre Benite, Not set
Research Site, Poitiers, Not set
Research Site, Rennes, Not set
Research Site, Toulouse, Not set
Research Site, Tours, Not set
Research Site, Berlin, Not set
Research Site, Düsseldorf, Not set
Research Site, Essen, Not set
Research Site, Hamburg, Not set
Research Site, Heidelberg, Not set
Research Site, Wuerzburg, Not set
Research Site, Athens, Not set
Research Site, Rio, Not set
Research Site, Thessaloniki, Not set
Research Site, Haifa, Not set
Research Site, Jerusalem, Not set
Research Site, Petah Tikva, Not set
Research Site, Tel Aviv, Not set
Research Site, Tel Hashomer, Not set
Research Site, Brescia, Not set
Research Site, Fukushima-shi, Not set
Research Site, Kanazawa-shi, Not set
Research Site, Kashiwa-shi, Not set
Research Site, Kita-ku, Not set
Research Site, Kumamoto-shi, Not set
Research Site, Matsumoto-shi, Not set
Research Site, Nagoya-shi, Not set
Research Site, Shibuya-ku, Not set
Research Site, Seoul, Not set
Research Site, Seoul, Not set
Research Site, Seoul, Not set
Research Site, Gdańsk, Not set
Research Site, Warszawa, Not set
Research Site, St. Petersburg, Not set
Research Site, Barcelona, Not set
Research Site, Barcelona, Not set
Research Site, Gijón, Not set
Research Site, Granada, Not set
Research Site, Madrid, Not set
Research Site, Madrid, Not set
Research Site, Majadahonda, Not set
Research Site, Pamplona, Not set
Research Site, Salamanca, Not set
Research Site, Sevilla, Not set
Research Site, Valencia, Not set
Research Site, Glasgow, Not set
Research Site, London, Not set
Conditions: AL Amyloidosis
A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis
Completed
The purpose of this study is to evaluate the efficacy and safety of daratumumab plus cyclophosphamide, bortezomib and dexamethasone (CyBorD) compared with CyBorD alone in treatment of newly diagnosed amyloid light chain (AL) amyloidosis participants.
The purpose of this study is to evaluate the efficacy and safety of daratumumab plus cyclophosphamide, bortezomib and dexamethasone (CyBorD) compared with CyBorD alone in treatment of newly diagnosed amyloid light chain (AL) amyloidosis participants. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/22/2025
Locations: Mayo Clinic Arizona, Phoenix, Arizona +139 locations
Mayo Clinic Arizona, Phoenix, Arizona
City of Hope, Duarte, California
University of California San Francisco, San Francisco, California
Stanford University, Stanford, California
University of Colorado, Aurora, Colorado
Colorado Blood Cancer Institute, Denver, Colorado
Mayo Clinic, Jacksonville, Florida
Winship Cancer Institute Emory University, Atlanta, Georgia
University of Maryland, Baltimore, Maryland
Tufts Medical Center, Boston, Massachusetts
Boston University Medical Center, Boston, Massachusetts
Dana Farber Cancer Institute, Boston, Massachusetts
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan
Mayo Clinic Rochester, Rochester, Minnesota
Washington University School Of Medicine, Saint Louis, Missouri
Columbia University Medical Center, New York, New York
Weill Cornell Medical College, New York, New York
University of Rochester Medical Center, Rochester, New York
Levine Cancer Institute, Charlotte, North Carolina
Wake Forest University Health Sciences - Cardiovascular Medicine, Winston-Salem, North Carolina
Cleveland Clinic, Cleveland, Ohio
The Ohio State University, Columbus, Ohio
Oregon Health And Science University, Portland, Oregon
University of Pennsylvania Medical Center, Philadelphia, Pennsylvania
Sarah Cannon Research Institute, Nashville, Tennessee
Vanderbilt University Medical Center, Nashville, Tennessee
University of Texas, MD Anderson Cancer Center, Houston, Texas
Huntsman Cancer Institute, Salt Lake City, Utah
Seattle Cancer Care Alliance, Seattle, Washington
Box Hill Hospital, Box Hill, Not set
Sir Charles Gairdner Hospital, Nedlands, Not set
Westmead Hospital, Westmead, Not set
Princess Alexandra Hospital, Woolloongabba, Not set
Institut Jules Bordet, Anderlecht, Not set
UZ Gent, Gent, Not set
Az Groeninge, Kortrijk, Not set
Universitair Ziekenhuis Leuven, Leuven, Not set
Hospital das Clinicas de Porto Alegre, Porto Alegre, Not set
Sociedade Pernambucana de Combate ao Cancer, Recife, Not set
Instituto de Educacao, Pesquisa e Gestao em Saude Instituto Americas (COI), Rio de Janeiro, Not set
Hospital Sao Rafael, Salvador, Not set
Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto Hospital de Base, Sao Jose do Rio Preto, Not set
Instituto de Assistencia Medica ao Servidor Publico Estadual IAMSPE, Sao Paulo, Not set
Clinica Sao Germano, São Paulo, Not set
Hospital Das Clinicas Da Faculdade De Medicina Da USP, São Paulo, Not set
Arthur J E Child Comprehensive Cancer Centre, Calgary, Alberta
Alberta Health Services, Edmonton, Alberta
Vancouver General Hospital, Vancouver, British Columbia
London Health Sciences Center, London, Ontario
University Health Network UHN Princess Margaret Cancer Centre, Toronto, Ontario
McGill University Health Centre, Montreal, Quebec
Peking University First Hospital, Beijing, Not set
Peking University People s Hospital, Beijing, Not set
First affiliated Hospital of Zhejiang University, Hangzhou, Not set
Ruijin Hospital Shanghai Jiao Tong University, Shanghai, Not set
The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Not set
Aarhus University Hospital, Aarhus N, Not set
Dep. of Hematology, Rigshospitalet, Copenhagen, Not set
Odense Universitets Hospital, Odense, Not set
CHU Dijon, Dijon, Not set
Hopital Claude Huriez, Lille cedex, Not set
CHU de Limoges - Fédération Hépatologie, Limoges, Not set
Institut Paoli Calmettes, Marseille, Not set
Chu Hotel Dieu, Nantes cedex 01, Not set
Hopital Saint Louis, PARIS cedex 10, Not set
Centre hospitalier Lyon-Sud, Pierre - Bénite cedex, Not set
CHU De Poitiers, Poitiers, Not set
CHU Rangueil, Toulouse, Not set
CHU Bretonneau, Tours cedex, Not set
CHU de Nancy_ Hopital Brabois, Vandoeuvre les Nancy, Not set
Charite Campus Benjamin Franklin, Berlin, Not set
Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Not set
Universitatsklinikum Essen, Essen, Not set
HOPA-Hämatologisch-Onkologische Praxis Altona MVZ GmbH, Hamburg, Not set
Universitaetsklinikum Heidelberg Medizinische Klinik V, Heidelberg, Not set
Universitaetsklinikum Tuebingen der Eberhard-Karls-Universitaet, Abteilung fuer Innere Medizin II,, Tübingen, Not set
Universitätsklinikum Würzburg Med. Klinik U. Poliklinik Ii, Würzburg, Not set
Alexandra General Hospital of Athens, Athens, Not set
University General Hospital of Rio, Patra, Not set
Semmelweis Egyetem I.Belgyogyaszati Klinika, Budapest, Not set
Semmelweis Egyetem I.Belgyogyaszati Klinika, Budapest, Not set
Del Pesti Centrumkorhaz Orszagos Hematologiai es Infektologiai Intezet Szent Laszlo Telephely, Budapest, Not set
Carmel Hospital, Haifa, Not set
Hadassah Medical Center, Jerusalem, Not set
Sheba Medical Center, Ramat-Gan, Not set
Sourasky Medical Center, Tel-Aviv, Not set
Assaf Ha'Rofeh Medical Center, Zerifin, Not set
Policlinico di Bari, Bari, Not set
Istituto di Ematologia Seràgnoli azienda ospedaliera univeristaria Policlinico S.Orsola-Malpighi, Bologna, Not set
Casa di Cura La Maddalena, Palermo, Not set
Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo, Pavia, Not set
Dipartimento Di Biotecnologie Cellulari Ed Ematologia-Università ''La Sapienza'',Policlinico Umberto I, Roma, Not set
A.O.U. Città della Salute e della Scienza, Torino, Not set
Fukushima Medical University Hospital, Fukushima, Not set
Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital, Hiroshima, Not set
Teine Keijinkai Hospital, Hokkaido, Not set
Kanazawa University Hospital, Kanazawa, Not set
Kumamoto University Hospital, Kumamoto-City, Not set
Kyoto Kuramaguchi Medical Center, Kyoto, Not set
Shinshu University Hospital, Matsumoto, Not set
Matsuyama Red Cross Hospital, Matsuyama, Not set
Nagoya City University Hospital, Nagoya, Not set
National Hospital Organization Okayama Medical Center, Okayama, Not set
Japanese Red Cross Medical Center, Shibuya, Not set
Tokushima University Hospital, Tokushima, Not set
Pusan National University Hospital, Busan, Not set
Seoul National University Hospital, Seoul, Not set
Severance Hospital Yonsei University Health System, Seoul, Not set
Samsung Medical Center, Seoul, Not set
The Catholic University of Korea Seoul St Marys Hospital, Seoul, Not set
Centro de Investigación Farmacéutica Especializada, Guadalajara, Not set
Hospital Universitario Dr Jose Eleuterio Gonzalez, Monterrey, Not set
Haga ziekenhuis, Den Haag, Not set
UMCG, Groningen, Not set
Erasmus MC, Rotterdam, Not set
UMC Utrecht, Utrecht, Not set
Maxima Medisch Centrum, Veldhoven, Not set
Samodzielny Publiczny Zaklad Opieki Zdrowotnej Zespol Szpitali Miejskich, Chorzow, Not set
SKPP UM w Poznaniu, Poznan, Not set
Instytut Hematologii i Transfuzjologii, Warszawa, Not set
Inst. Cat. D'Oncologia-Badalona, Badalona, Not set
Hosp Univ Vall D Hebron, Barcelona, Not set
Hosp Clinic de Barcelona, Barcelona, Not set
Hosp. Univ. Ramon Y Cajal, Madrid, Not set
Hosp Univ Fund Jimenez Diaz, Madrid, Not set
Hosp. Univ. 12 de Octubre, Madrid, Not set
Clinica Univ. de Navarra, Pamplona, Not set
Hosp Clinico Univ de Salamanca, Salamanca, Not set
Hosp. Univ. de Canarias, San Cristóbal de La Laguna, Not set
Hosp. Univ. Dr. Peset, Valencia, Not set
South Elvsborg Hospital, Boras, Not set
Skanes universitetssjukhus, Lund, Not set
Ankara Universitesi Tip Fakultesi Cebeci Hastanesi, Ankara, Not set
Akdeniz University Medical Faculty, Antalya, Not set
Ondokuz Mayis Universitesi Tip Fakultesiy, Atakum, Not set
Istanbul University Istanbul Medical Faculty, Istanbul, Not set
Dokuz Eylul Universitesi Tip Fakultesi, Izmir, Not set
Erciyes University Medical Faculty, Talas, Not set
University Hospitals Birmingham NHS Trust,, Birmingham, Not set
University College Hospital, London, Not set
Conditions: Amyloidosis
37 - 48 of 187